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 Biocatalysts are increasingly prevalent in the large-scale synthesis of 
enantiomerically pure compounds, which are mainly used as active pharmaceutical 
ingredients. Enantiomerically pure forms can lead to lower dosages, improved efficacy, 
and even allow for extension of patents. However, many sought-after reactions lack a 
suitable enzymatic production route. A recent assessment by the ACS Green Chemistry 
Institute, Pharmaceutical Roundtable noted that the asymmetric synthesis of amines from 
prochiral ketones and free ammonia was one of the top aspirational reactions challenging 
the pharmaceutical industry.  
 The first goal of this work was developing an amine dehydrogenase through the 
application of directed evolution altering the substrate specificity of an existing leucine 
dehydrogenase scaffold. The resulting amine dehydrogenase asymmetrically would 
convert methyl isobutyl ketone to 1, 3-dimethyl butyl amine. Eleven rounds of directed 
evolution completely altered the enzyme’s specificity and successfully created amination 
activity. These variants were screened by various high-throughput assays identifying 
minute increases in amination activity, and successful mutations were carried into future 
rounds of mutagenesis. The resulting quadruple mutant, K67S/E113V/N261L/V290C 
exhibited novel reductive amination activity of 0.69 U mg
-1
 with a corresponding kcat 
value of 0.46 s
-1
. The enantioselectivity of the wild-type enzyme was maintained despite 
the drastic changes to the binding pocket and yielded (R)-1,3-DMBA with an e.e. value 
of 99.8% at 92.5% conversion making it an attractive catalyst in the synthesis of chiral 
amines. This was the first example of a cofactor-dependent amine dehydrogenase capable 
of selectively synthesizing chiral amines from a prochiral ketone and free ammonia. 
 xix 
 The second goal was to develop another amine dehydrogenase by applying these 
previously identified, influential mutations to a phenylalanine dehydrogenase scaffold. A 
single library of the two most influential residues was screened by a stringent 
absorbance-based assay. The resulting K77S/N276L double variant enhanced the desired 
reductive amination activity to a kcat value of 6.85 s
-1
 at 25 °C. The high 
enantioselectivity was maintained with an e.e. value of > 99.8% toward the (R)-
enantiomer. When paired with a cofactor recycle system, conversions in excess of 90% 
were achieved while maintaining selectivity. This second amine dehydrogenase exhibits 
significantly enhanced activity and different substrate specificity compared to the 
previous enzyme.  
The final goal of this work was to test the applicability of the mutations 
responsible for amine dehydrogenase activity across related scaffolds in the enzyme’s 
sub-family. During the evolutionary route of producing the aforementioned enzymes, the 
evolutionary process concurrently identified two mutations as essential for amination 
activity. The mutation of these residues is believed to be broadly applicable across the 
Glu-Leu-Phe-Val dehydrogenase sub-family of enzymes. To test this hypothesis, a third 
scaffold from valine dehydrogenase will be evolved at its analogous residues for amine 
dehydrogenase activity, potentially giving credence to a novel enzyme family. 
 Lastly, future works are discussed exploring the applicability of this enzyme to 







 Enzymes are unique in their ability to significantly enhance reaction rates under 
mild conditions with high levels of efficiency and selectivity. After substrates have bound 
to an enzyme’s active site, their half-life is usually only a fraction of a second (1). Some 
enzymes perform catalysis so well they border on the physical limitations of efficiency 
with encountering substrate in solution, and have been known to achieve rate 
enhancements (kcat/kuncat) in excess of 19 orders of magnitude. These outstanding 
examples of enzymatic catalysis establish their remarkable power, and demonstrate their 
potential use in chemical synthesis. 
 In addition to rate enhancement, many enzymes are selective in their catalysis and 
allow for the direct production of single enantiomers. Single enantiomers of target 
product molecules have a large importance in the pharmaceutical and agricultural 
industries. Therapeutic compounds often act as structurally optimized inhibitors of 
biological processes. Since the human body functions using chiral chemistry, these 
compounds almost always contain chiral centers. In 2006, 80% of small-molecule drugs 
approved by FDA were chiral and 75% were single enantiomers (2). Current USA Food 
and Drug Administration (FDA) regulations require proof that any non-therapeutic 
isomer comprising over 1% of the total composition be non-teratogenic. Thus, a racemic 
drug would require separate toxicology studies of each enantiomer. Further, as the 
complexity of these compounds increases, molecules often require more than one chiral 
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center (3). It is common for pharmaceutical processes to require a minimum acceptable 
enantiomeric excess (e.e.) of 98% to circumvent these difficulties.  
 Chiral intermediates are classically prepared by three different routes (4). One 
method is to simply attain them through a naturally occurring chiral synthon. This allows 
for an inexpensive and readily available source of natural products, but this pool of 
compounds is limited. Alternatively, chirality can be achieved through the resolution of a 
racemic mixture, as seen in the kinetic resolution of alcohols and amines through the 
application of lipases or esterases (5-7). The major disadvantage of kinetic resolution is 
an unfavorable equilibrium constant, usually near unity. The use of a second reaction is 
required to drive the reaction to completion. Lastly, the chiral centers can be synthesized 
directly using an asymmetric catalyst or enzyme. If the desired selectivity is not achieved 
initially, multiple enrichments, such as crystallization, can be required to achieve an 
increased selectivity. In comparison to other catalysts, enzymes usually offer superior 
enantio- and regioselectivity, commonly reporting e.e.’s of > 99.9% (8). High initial 
selectivity eliminates the need for enrichment, significantly reducing the cost of 
production.  
 One of the short comings of biocatalysis is the limited number of reactions which 
have identified enzymatic routes. In 2005, the American Chemical Society’s (ACS) 
Green Chemistry Institute (GCI) and several leading global pharmaceutical companies 
created the ACS GCI Pharmaceutical Roundtable. The goals of this center encompassed 
innovation in the discovery, development, and production of pharmaceuticals. 
Consequently, the Roundtable identified the most aspirational reactions currently 
challenging the pharmaceutical industry (Table 1.1) (9). The reductive amination of a 
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prochiral ketone with free ammonia to produce chiral amines ranked second on this list, 
and had yet to be achieved. 
 
Table 1.1. Aspirational reactions challenging the pharmaceutical industry as determined 
by the ACS GCI Pharmaceutical Roundtable (9). 
 
Research Area Number of Roundtable com-
panies voting for this research 
area as a priority area 
C–H activation of aromatics (cross coupling reactions avoiding the 
preparation of haloaromatics) 
6 votes 
Aldehyde or ketone + NH3 + ‘‘X’’ to give chiral amine 4 votes 
Asymmetric hydrogenation of unfunctionalized olefins/enamines/imines 4 votes 
New greener fluorination methods 4 votes 
N-Centered chemistry avoiding azides, hydrazine etc 3 votes 
Asymmetric hydramination 2 votes 
Green sources of electrophilic nitrogen (not TsN3, nitroso, or diimide) 2 votes 
Asymmetric hydrocyanation 2 votes 
 
 
 This work achieves exactly this reaction through the evolution of an amino acid 
dehydrogenase scaffold to an amine dehydrogenase. Developments in recombinant 
technology have allowed for expansion to the biocatalysis repertoire, in turn enabling 
new chemistries. Directed evolution has emerged as a common tool in the creation of 
novel enzymes. Directed evolution involves the introduction of mutations to a parent 
enzyme, followed by screening or selection of these variants for a desired property, and 
propagation of these beneficial mutations into subsequent cycles of mutagenesis to 
achieve a desired property. 
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 To apply this process, a robust and sensitive high-throughput assay has been 
developed allowing identification of favorable mutations. Eleven rounds of mutagenesis 
had completely altered the substrate specificity resulting in the asymmetric amination of 
methyl isobutyl ketone to (R)-1, 3-dimethyl butyl amine, while maintaining high 
selectivity and conversion. The influential mutations were identified and inserted into an 
analogous scaffold of phenylalanine dehydrogenase, further increasing the substrate 
specificity and activity of AmDHs. These mutations will lead to the possible creation of a 
family of AmDHs. 
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CHAPTER 2 
STATUS OF PROTEIN ENGINEERING FOR BIOCATALYSTS: 
HOW TO DESIGN AN INDUSTRIALLY USEFUL BIOCATALYST 
   
2.1 Introduction 
 Recent advances in the development of both experimental and computational 
protein engineering tools have enabled a number of further successes in the development 
of biocatalysts ready for large-scale applications. Key tools are first, the targeting of 
libraries, leading to far smaller but more useful libraries than in the past, second, the 
combination of structural, mechanistic, and sequence-based knowledge often based on 
prior successful cases, and third, the advent of sequence and structural based algorithms 
allowing the design of novel functions (10-13). Based on these tools, a number of 
improved biocatalysts for pharmaceutical applications have been presented, such as an 
(R)-transaminase for the synthesis of active pharmaceutical ingredients (APIs) of 
sitagliptin (Januvia®) and ketoreductases, glucose dehydrogenases, and haloalkane 
dehalogenases for the API synthesis toward atorvastatin (Lipitor®) and montelukast 
(Singulair®) (14-18). 
 The ideal industrial biocatalyst should have high specific activity combined with 
high specificity on the reactant in question, the highest possible enantioselectivity in case 
of generating a chiral center, and should be stable at industrial process conditions, that is, 
often higher than ambient temperature and in partially or wholly nonaqueous solvents. 
The advent of molecular biology since the late 1970’s embodied in protein engineering 
protocols; progress in crystallography and computational methods has enabled the design 
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of protein catalysts for targeted applications and improvement of desired traits. When 
starting any protein engineering project, two questions must be asked, ‘what template 
should I start with?’ and ‘what tools should I use from the biocatalyst toolbox?’ Protein 
engineering has evolved from its first phase of rational design to the second phase with 
combinatorial design or ‘directed evolution’, and most recently to the third phase, data-
driven design of biocatalysts. No longer is a large library size the driving attribute for 
protein development but instead a small number of targeted libraries, which embody a 
restricted range of codons and predictive tools optimizing the trait in question.  
 This chapter covers the progress in protein engineering over the last few years and 
describes status and perspectives for biocatalyst design and optimization. 
2.2 Protein engineering tools 
 Numerous protein engineering tools have emerged in recent years for the 
improvement of existing biocatalysts or for their adaptation to novel substrates. Table 2.1 
lists a number of different enzymes that have been evolved over the past few years along 
with the key results from these protein engineering efforts. The selection of protein 
engineering tools depends upon the following criteria:  
(i) The expected involvement of amino acid residues close or distant to the 
active site: changes in activity or selectivity often involve residues close to 
the active site, where improvements in stability in most cases require 
targeting residues away from the active site (19). 
The library screening capacity: whereas combinatorial design strove for 
the largest possible library sizes, topped by selection (growth-based 
selection: up to 10
12




 variants for 
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screening with fluorescent (such as fluorescence-activated cell sorting, 
FACS (20)) or spectrophotometric assays, data-driven protein engineering 
strives for the smallest possible library, usually lower than 100,with the 
techniques described below. 
(iii) The depth and accuracy of available sequence and structure information: 
crystal structures accurate to < 1 Å allow positioning of water, often 
critical to the catalytic mechanism (21, 22), while many data-driven 
concepts (see below) depend on the availability of as many as possible 
sequences with the maximum possible level of identity for accurate 
predictions. 
A description of individual tools follows. 
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Table 2.1. Selected results from protein engineering of biocatalyst (23). 
 
Enzyme Protein engineering goal Tools Metric(s) Ref. 
ATA-117 D-amino 
acid transferase 










200 g/L substrate 
converted with >99.95% 
ee, 92% assay yield 














ProSAR >100 g L
-1
 substrate 
converted with >99% ee 
(template had 63% ee), 
>99% assay yield obtained 








t1/2 > 3.5 days at 65 °C       
(x 10
6












converted with >99.9% ee, 
95% isolated yield 
obtained in  ~8 h 
(27) 
Kemp eliminase Novel catalysis De novo design 
via Rosetta, 
directed evolution 
kcat = 1.375 s
-1
,           



















based on docking 
knowledge 
Indirubin/indigo ratio = 9 
(51-fold improvement) 
(30) 









Diels-Alderase Novel catalysis De novo design 
via Rosetta 
kcat = 0.036 s
-1
;           








Improved thermostability SCHEMA T50 = 65.7 °C, increased    




2.2.1 Iterative saturation mutagenesis 
 Iterative saturation mutagenesis (ISM) has become known as an essential tool in 
designing novel biocatalysts (35). The saturation of individual residues has been proven 
to create novel functionality, enantioselectivity, and thermostability. The incremental 
accumulation of single site mutations likely mirrors the evolutionary path of nature (36), 
although this stepwise procedure is not the most direct method and will likely miss any 
synergistic effects from neighboring residues (37). 
2.2.2 Combinatorial active-site saturation testing 
 Combinatorial active-site saturation testing (CASTing) is another powerful tool 
for developing more active, thermostable, or selective mutants (35). CASTing’s 
usefulness lies in its ability to test the synergistic effects of saturating small portions of 
the protein’s active site. However, CASTing libraries can easily exceed screening 
capacity because of the exponential growth of the screening requirement with each 
additional mutation. A four position NNK library would result in 32
4
 codons and a 
screening requirement of > 10
6
 colonies. CASTing is best applied when activity toward 
the desired substrate already exists at some level, otherwise low levels of activity may be 
missed depending on the precision of the screening assay (Chapters 3-5 are an exception 
to the strategy). Despite their low activity, these transitional mutants are essential in the 
iterative process to a successful catalyst. The B-FIT approach (35, 38), a variation of 
CASTing based on the temperature dependence of spatial flexibility of residues (B-
factor), targets amino acid positions based on high crystallographic B-factors indicating 
high flexibility associated with positions in the crystal structure to improve 
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thermostability. This method successfully improved a lipase (lipA) but needs further 
corroboration with other examples (35). 
2.2.3 Restricted libraries  
 One of the simplest ways to improve screening efficiency is the appropriate 
application of degenerate codons. Degenerate codons can be used to limit mutation of 
target sites to a desirable group of amino acids. Selection of the allowed mutations can be 
restricted based on rational design (39, 40) or broad mutation to efficient codons, such as 
NDT. While NDT limits the mutation to 12 diverse amino acids (from 12 codons), it 
removes the redundancy of analogous codons seen in conventional NNK codon 
degeneracy (20 amino acids/32 codons, including a stop codon) (41, 42). Further 
restriction of degenerate codons can be used to reduce library size even further (43) and 
was successfully used by Jochens et al. by restricting codon usage based on 3DM 
analysis of the α/β hydrolase fold family (41, 44). 
2.2.4 Structure-guided consensus  
 The structure-guided consensus technique combines sequence-based and 
structural data and employs a set of phylogenetically diverse but functionally proven 
proteins. The resulting alignment of sequences often has a relatively low level of 
sequence identity (40–80%) (13). From this alignment, mutational points-of-interest are 
limited to those positions which match the desired consensus cut-off. Further constriction 
of the remaining residues is achieved via structural criteria, such as keeping a distance 
from the active site (often 4-8 Å), introducing helix stabilizers, and not breaking salt-
bridge formation. The remaining consensus mutants are expressed and screened as single 
and multiple residue mutants for thermostability. The result is a highly constrained 
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mutational space, which has been shown to contain an increased percentage of 
thermostable mutants. 
 Lately, significant advances in protein engineering have come through 
computational methods. Computational design greatly decreases the need of probing 
randomized sequence space, rendering the route to novel biocatalyst much more efficient. 
Several significant approaches to rational design have been introduced over the last few 
years. The most prominent of these methods are SCHEMA, ProSAR, and ROSETTA. 
2.2.5 SCHEMA 
SCHEMA is a computational algorithm which estimates the amount of disruption to a 
protein structure upon caused DNA recombination. Libraries of chimeras are scored (E = 
average disruption) according to the number of residue–residue contacts which broken 
when compared to the parent proteins. Screening can then be focused to those chimeras 
with less structural disruption (low E). The SCHEMA algorithm ultimately results in an 
enhanced probability of functional chimeras with relatively low identity to the parent 
sequences, effectively generating a family of diverse, folded, and functional proteins 
(45). Additionally, many nonfunctional chimeras with low E have regained activity by 
low error-rate random mutagenesis (11). 
2.2.6 ProSAR 
  Richard Fox et al. have developed a strategy for improving recombination-based 
directed evolution by applying statistical analysis of PROtein Sequence Activity 
Relationships (ProSARs) (10). After initially screening a diverse group of mutants for 
activity toward the desired function, this data is applied to the ProSAR model as a 
training set. The ProSAR model sorts mutations based on their predicted effect on 
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activity. Once beneficial mutations are identified, they are fixed for subsequent rounds. 
After each iteration, the resulting mutants showed constant improvement over the parent 
protein.  
2.2.7 Rosetta  
 Currently the Rosetta methodology (12, 28, 46) is the most rational of the 
computational techniques. Rosetta applies the quantum mechanical and computational 
design of the active site around a reaction’s transition state to create a novel biocatalyst 
from an existing template structure. This method has been shown to create Diels-
Alderase and previously nonexistent Kemp eliminase enzymes (12, 28, 47, 48). Despite 
exhibiting relatively low catalytic activity, they achieve some level of base activity to be 
improved upon (46). As protein structure–function knowledge advances to incorporate 
further interactions, purely rational techniques such as Rosetta will create increasingly 
robust enzymes. 
2.3 Protein engineering challenges 
 One of the most difficult problems in protein engineering is obtaining new 
function with an enzyme that has no detectable initial activity of the desired substrate. 
Peisajovich and Tawfik suggested that the commonly cited first rule of directed evolution 
‘you get what you select/screen for’ should be followed by a second rule of ‘you should 
select for what is already there’ (49). While there are exceptions to every rule, obtaining 
that initial activity does seem to be the key to further success. Gerlt and Babbitt describe 
enzyme (re)design from a variety of different templates; however, these (re)designs still 
need to improve to reach activity levels required for industrial catalysts, with kcat’s 
ranging between 0.000007 and 3.9 s
-1
 (50). Random mutagenesis has been the most 
 13 
common approach to tackling this problem, it is of interest to move toward more rational 
approaches to decrease screening effort and increase understanding (51). An algorithm on 




Figure 2.1. Protein engineering toolbox and design algorithm toward an industrial 
catalyst (23). 
 
2.3.1 Proposed algorithm to design an industrial biocatalyst 
Step 1: select the template  
 The question of what template to start with often puzzles the researcher and is not 
often discussed in the literature, as most papers just start with a statement of which 
protein was chosen. Should one start with a more ancestral protein with many 
 14 
promiscuous (but low) activities?, a very stable template?, a highly active protein that has 
poor selectivity?, and an easily expressible protein with high expression levels? Often 
these criteria are mutually exclusive, so how does one prioritize?  
 We propose that a template that has the most desirable reaction properties should 
be selected as the starting point, preferably one with some activity toward the target 
substrate. Clearly, this is not possible when no class of enzymes exists for the desired 
reaction, in which case one would have to apply the de novo approaches. One of the best 
methods of selecting a template enzyme has been developed by Höhne et al. and is based 
on an in silico analysis of multiple sequences, structures, and motifs that led straight to 
selection of a template with desirable properties without necessarily requiring Steps 2–4 
(52, 53).  
Step 2: stabilize the template  
 Thermostability, often closely related to organic solvent stability (25, 54), is an 
important parameter in the development of industrially applicable biocatalysts. Improved 
thermostability increases the life of the enzyme and the number of total turnovers that the 
enzyme can perform over the life of the catalyst, known as total turnover number (TTN). 
Several different protein engineering techniques have been successfully used to improve 
protein thermostability, including error-prone PCR (epPCR) (55), DNA shuffling via 
SCHEMA (11, 32, 33, 45, 56), temperature value (B-FIT) approach (35, 38) and the 
structure-guided consensus concept (26), all of which except epPCR require additional 
structural information. In addition to improved enzyme life, thermostability has been 
linked to the ability of an enzyme to tolerate destabilizing mutations (36, 49, 57, 58). The 
selection of the starting template can also influence the result of gaining new catalytic 
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function. ‘Neutral’ drifted and thermostabilized templates have higher tolerance for 
mutations, as such they can tolerate considerable mutation toward new specificities. 
‘Neutral’ drift is achieved by introducing random mutations (such as epPCR or DNA 
shuffling) and selecting those variants for wild-type activity (49, 57, 58). Thus, ‘neutral’ 
mutations are accumulated in the library in and around the active-site that may increase 
promiscuity. The ‘neutral’ drift method is highly dependent on an effective high-
throughput screen or selection assay to obtain the library of neutral mutations. However, 
it is very straightforward to create a consensus sequence and one does not require any 
high-throughput selection to do so. The TEM-1 β-lactamase neutral drift evolution by 
Bershtein et al. demonstrated that all stabilizing mutations discovered using directed 
evolution drifted back to the consensus sequence (57). Therefore, moving toward a 
thermostabilized template, via the consensus sequence as described in section ‘Protein 
engineering tools’, before introducing libraries toward altered substrate specificity will 
increase the number of active variants and have the highest degree of success.  
Step 3: semi-rational design around the active-site  
 To design toward altered substrate specificity or enantioselectivity, mutations 
around the active site should be chosen (19). Rational design using the tools described in 
section ‘Protein engineering tools’, in particular CASTing, ISM and restricted codon 
libraries.  
Step 4: machine-based learning via recombination  
 Lastly, machine-based learning, such as ProSAR, remains the most effective way 
to improve an enzyme with small library sizes. 
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2.4 Successful case studies 
 One of the most successful industrial biocatalyst redesigns was the development 
of the ATA-117 D-amino acid amino transferase for the Januvia™ (Sitagliptin 
phosphate) process. A truncated substrate was used to overcome the lack of activity on 
their target substrate (17). The wild-type enzyme had detectable activity (albeit low  ~4% 
conversion after 24 hr) toward the truncated substrate. Savile et al. were able to use semi-
rational design via transition state docking to improve the activity toward the truncated 
substrate, resulting in an enzyme capable of aminating the target substrate at low 
conversion (< 1% conversion after 24 hr). After several more rounds of targeted and 
random mutagenesis via ProSAR, an enzyme designed for industrial yields and operating 
conditions was developed. Ultimately, the final enzyme contains 27 mutations both 
around the active-site and at the dimer interface.  
 Approaches that also target the active site such as CAST-ing along with structural 
information from docking studies have generated some very well developed biocatalysts. 
Iterative CASTing and ISM have also been successfully used toward improved 
enantioselectivity (31). This technique was most recently used to generate enoate 
reductases mutants that were both (R)- and (S)-selective (37). Hu et al. discovered a 
cytochrome P450 BM-3 mutant that altered the regioselectivity of the P450 BM-3 toward 
indirubin through the evaluation of a single NNK library that was designed based on 
docking studies (30).  
 Codexis has successfully applied ProSAR (in conjunction with directed evolution) 
to enhance the activity and enantioselectivity of several keto-reductases toward 
industrially relevant substrates. During this process, the resulting catalysts are also 
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optimized toward the desired industrial reaction conditions (14, 24, 27, 59). Other 
successful approaches include the computational design of active sites. The Baker lab has 
been successful using the Rosetta algorithm to design de novo biocatalysts including a 
Kemp elimination enzyme (46, 60) and a Diels-Alderase (12). These catalysts challenge 
our understanding on structure–function relationships and significantly broaden our 
ability to design catalysts not found in nature. Though, this technique requires significant 
improvement, as the catalytic rates are slow relative to naturally occurring enzymes, 
owing to the lack of malleability (i.e. excessive stiffness) of the protein binding site and 
active-site epitope and thus far the catalytic constants kcat are mostly < 1 s
-1
, far below 
what is required of a viable industrial catalyst. A significantly improved situation 
concerns Rosetta’s application to design orthogonal nucleoside kinases: the algorithm 
resulted in successfully identified residues for specificity change and suggested mutations 
to create the concerted mechanism required for selectivity (29). 
2.5 Future outlook of protein engineering of biocatalysts  
 The trend of improving proteins with targeted libraries incorporating structural 
and mechanistic knowledge as well as algorithms for interpreting data points on the 
function-sequence map likely will continue and even accelerate. Less dependence on 
large-scale screening equipment and ultimately a higher hit rate per unit of resource spent 
drive this development.  
2.6 Conclusions  
 Several of the described tools, such as targeted libraries, restricted codons, or 
structure-guided consensus, have contributed to improve biocatalysts to levels useful in 
large-scale applications. Computational methods for improved reactivity based on 
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structures, i.e. that is, a structural picture of the transition state, seem to require further 




DEVELOPMENT OF A NOVEL AMINE DEHYDROGENASE FROM 
LEUCINE DEHYDROGENASE 
   
3.1 Introduction 
 Biocatalysts are increasingly prevalent in the large-scale synthesis of 
enantiomerically pure compounds (EPCs), which are mainly used as active 
pharmaceutical ingredients (APIs). Enantiomerically pure forms can lead to lower 
dosages, improved efficacy, and even allow for extension of patents (61). In 2006, 80% 
of small-molecule drugs approved by FDA were chiral and 75% were single enantiomers 
(2). However, many sought-after reactions lack a suitable enzymatic production route. A 
recent assessment by the ACS Green Chemistry Institute, Pharmaceutical Roundtable 
noted that the asymmetric synthesis of amines from prochiral ketones and free ammonia 
was one of the top aspirational reactions challenging the pharmaceutical industry (Figure 
1.1) (9).  
 Our novel enzyme achieves exactly that aim: it creates amines with high 
selectivity. Previously characterized amine dehydrogenases were incapable of effecting 
the reductive amination of ketones and lacked stereoselectivity (62). 
 While chiral amines can be produced both chemically and enzymatically, the 
large-scale production of chiral amines is still challenging and heavily reliant on 
traditional methods of chemical synthesis (27, 61, 63-65). Common methods include 
resolution though fractional crystallization (66) and the hydrogenation of C=N bonds, 
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particularly in enamines (67). Nonetheless, some chemoenzymatic routes, particularly 
with transaminases (47, 68-71),  have shown promise in the dynamic kinetic resolution of 
racemic amines (70, 72, 73) and the direct asymmetric synthesis of amines with ω-
transaminases (ω-TA), as used in the synthesis of sitagliptin (74-76). This novel process 
has eliminated the use and removal of a less-selective rhodium catalyst, yet requires the 
use of a sacrificial amine source. The undesired ketone by by-product must also be 
removed to shift the reaction equilibrium beyond about 50% conversion.  
 Asymmetric synthesis by amine dehydrogenases (AmDHs) would be the ideal 
route to produce chiral amines. When paired with a cofactor recycling system, such as 
glucose/glucose dehydrogenase (GDH) or formate/formate dehydrogenase (FDH), amine 
dehydrogenases allow for the direct production of chiral amines, with the consumption of 
only an inexpensive reducing agent, such as glucose or formate, and free ammonia 
(Figure 3.1) (13, 27, 77, 78).  
 
 
Figure 3.1. Asymmetric synthesis reaction scheme with an amine dehydrogenase paired 
with a glucose dehydrogenase cofactor recycling system (79). 
 21 
 By using an existing amino acid dehydrogenase scaffold, we have successfully 
altered the substrate specificity through several rounds of protein engineering to create an 
amine dehydrogenase. Instead of the wild-type α-keto acid, the amine dehydrogenase 
now accepts the analogous ketone, methyl isobutyl ketone (MIBK), which corresponds to 
replalcement of the carboxyl moiety with a methyl group (Figure 3.2). The wild-type 




Figure 3.2. Reactions of wild type LeuDH and LeuDH-AmDH. A) Wild-type leucine 
dehydrogenase reaction. B) Novel amine dehydrogenase reaction (79). 
 
3.2 Materials and Methods 
3.2.1 gDNA preparation, gene isolation and overexpression 
 Leucine dehydrogenase (E.C. 1.4.1.9) from Bacillus stearothermophilus was 
donated by Assistant Professor Bert C. Lampson from East Tennessee State University, 
followed by isolation of the genomic DNA through application of method B described by 
Mehling et al. (80). The isolated gene (1104 bp) was inserted into pET17b vector (Life 
Technologies-Invitrogen, Grand Island, NY, USA) at the restriction sites NdeI and 
HindIII (New England Biolabs) using T4 DNA Ligase (Roche, South San Francisco, CA, 
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USA) at 16 °C, 8 hours. This allowed for overexpression upon transformation into E. coli 
BL21 DE3 competent cells (Life Technologies). Cultures were expressed at 37° C in LB 
media for 24 hours. Cultures were induced with IPTG at and OD600 between 0.4 and 0.6 
absorbance. Overexpression was evident by SDS-PAGE identifying a high protein 
concentration at 40.5 kDa (Figure 3.3). 
 
 
Figure 3.3. His-tag purification of wild-type LeuDH (42kDa). Lane L: Ladder, A: 
Clarified cell lysate, B: Unbound clarified cell lysate, C: 50 mM imidazole wash 1, D: 50 
mM imidazole wash 2, E: Pure protein elution fraction 1, F: Pure protein elution fraction 
2. 
  
3.2.2 Protein purification 
 For purification, proteins were expressed in pET28a vector (Life Technologies) in 
BL21 (DE3) with an N-terminal Histag. The gene was inserted in the vector at restriction 
sites NdeI and HindIII. His-tagged proteins were expressed in a similar manor as (Section 
 23 
3.2.1) at 37° C for 24 hours. His-tagged proteins were subsequently purified using 
immobilized metal ion affinity chromatography (IMAC) with a Ni-NTA resin (Thermo 
Scientific, Rockford, IL, USA). Cell culture pellets were made by centrifugation (4000 
rpm, 30 min, 4° C) in 50 mL aliquots. Cell pellets were resuspended in 50 mM phosphate 
buffer (6 mL) at pH 8.0 containing 20 mM imidazole and 300 mM NaCl. This was 
followed by sonication and centrifugation to remove cell debris. The clarified cell lysate 
was bound to the Ni-NTA resin by shaking on ice for 1 hour, and subsequently purified 
by column affinity chromatography. Protein-bound resin and clarified cell extract was 
poured over a column, and washed twice with 50 mm phosphate buffer (5 mL) at pH 8.0 
containing 50 mM imidazole and 300 mM NaCl. Purified protein was eluted with the 
same buffer solution containing 250 mM imidazole (2 mL). An SDS-PAGE gel of a 
representative purification can be seen below. The leucine dehydrogenase protein can be 





Figure 3.4. His-tag purification of K67S/E113V/N261L/V290C AmDH (42kDa). Lane 
L: Ladder, A: Pure protein elution fraction 2, B: Pure protein elution fraction 1, C: 50 
mM imidazole wash 2, D: 50 mM imidazole wash 1, E: Unbound clarified cell lysate, F: 
Clarified cell lysate. 
 
3.2.3 Spectrophotometric assay 
 Activity of purified proteins was measured using a spectrophotometric assay at 





) (81). For reductive amination, reactions took place in 500 mM 
NH4Cl/NH4OH at pH 9.6, with 200 μM NADH and 20 mM of the ketone substrate, 
unless otherwise specified. For oxidative deamination, reactions took place in 0.1 M 
NaHCO3/Na2CO3 buffer at pH 10.0, with 1 mM NAD+ with 10 mM of the amine 
substrate of interest. All reactions were performed at 25° C unless otherwise specified. 
Enzyme was added in 10 μL aliquots in dilute concentrations. Enzyme concentrations 
varied upon activity levels with the substrate present, but were dilute enough to ensure 
linear conversion kinetics over the analytical time period (10 min to 30 min). Specific 
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activities were then calculated from the stoichiometric conversion of cofactor as 
determine by the change in absorbance at 340 nm over time. 
3.2.4 Mutagenesis and library generation 
 Mutant libraries were generated using overlap extension PCR. After identification 
of mutational sites, primers were designed according to the guidelines of the 
QuikChange
®
 Site Directed Mutagenesis Protocol (Agilent Technologies, Santa Clara, 
CA, USA) (82). These primers were then used in the overlap extension protocol 
described in Molecular Cloning: A Laboratory Manual (83). The overlap extension 
method has several advantages. It requires the successive amplification of DNA 
segments, making it easier to troubleshoot than the blind success or failure of the 
Quikchange
®
 protocol. Additionally, the overlap extension method does not potentially 
carry over whole plasmid from the parent DNA into the final transformation. This 
significantly decreases the amount of non-mutated colonies present in the screened 
library. After mutation, the resulting mutated gene was digested using NdeI and HindIII, 
ligated into pET17b, and expressed as described in Section 3.2.1. A table of the primers 




Table 3.1. Table of forward (Fwd) and reverse (Rev) primers used in the generation of 
LeuDH mutant libraries. 
 
Library  Primer  
3 Fwd 5' AGGGCTGAACGGCCGCTACATTACGGBGNNTRABRTKGGCACGACCGTTGCCGATATGGA 3' 
Rev 5' ATCCATATCGGCAACGGTCGTGCCMAYVTYANNCVCCGTAATGTAGCGGCCGTTCAGCCCT 3' 
4 Fwd 5' ATTCATGACACGACGCTCGGCCCGGCGDBWGBCDBWACGCGCATGTGGATGTACAATTC 3' 
Rev 5' GAATTGTACATCCACATGCGCGTWVHGVCWVHCGCCGGGCCGAGCGTCGTGTCATGAAT 3' 
5 Fwd 5' GATTATGTGATCAACNNKGGCGGCGTCATCAACG 3' 
Rev 5' CGTTGATGACGCCGCCMNNGTTGATCACATAATC 3' 
6 Fwd 5' CAACGCCGGCGGCDBSATCAACDBSGCCGATGAGCTGTACGGC  3' 
Rev 5' GCCGTACAGCTCATCGGCSVHGTTGATSVHGCCGCCGGCGTTG  3' 
7 Fwd 5' CTGAACGGCCGCTACATTACGNNKGTTGACGTTGGCACGACCG 3' 
Rev 5' CGGTCGTGCCAACGTCAACMNNCGTAATGTAGCGGCCGTTCAG 3' 
8 Fwd 5' CGCCGGCGGCGTCNNKAACGTCGCCGATGAGCTGTA 3' 
Rev 5' TACAGCTCATCGGCGACGTTMNNGACGCCGCCGGCG 3' 
9 Fwd 5' CGTCATCAACGTCGCCGATNNKCTGTACGGCTACAACCGTGAACG 3' 
Rev 5' CGTTCACGGTTGTAGCCGTACAGMNNATCGGCGACGTTGATGACG 3' 
10 Fwd 5' CGCCGGCTCGGCGNNKAATCAGCTGAAAGAGCCGCG 3' 
Rev 5' CGCGGCTCTTTCAGCTGATTMNNCGCCGAGCCGGCG 3' 
11 Fwd 5' CCCGCGGCATGACGTACDDKAACGCGGCCGCCG 3' 
Rev 5' CGGCGGCCGCGTTMHHGTACGTCATGCCGCGGG 3' 
Fwd 5' CGCCGGCTCGGCGDDKAATCAGCTGAAAGAGCCGCG 3' 
Rev 5' CGCGGCTCTTTCAGCTGATTMHHCGCCGAGCCGGCG 3' 
 
 
 The randomized libraries were plated on Genetix 10” x 10” in. agar plates 
(Molecular Devices, Sunnyvale, CA, USA) containing 200 mL of LB-agar with 50 
μg/mL ampicillin, and allow to grow for 18-24 hours at 37 °C. The resulting colonies 
were autonomously picked using a Genetix QPix2 Colony Picker (Molecular Devices), 
and inoculated in 96-well microtiter plates containing 200 μL of LB media with 50 
μg/mL ampicillin (LB-AMP). The plates were covered in Parafilm M (Bremis, Neenah, 
WI, USA) to prevent cross contamination between wells, and incubated at 37 °C, 200 
rpm for 24 hours. The plates were then replicated into expression plates containing 250 
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μL of auto-inducing MagicMedia™ (Life Technologies) containing 50 μg/mL ampicillin. 
Glycerol (100 μL) was added to the LB-AMP ‘master’ plate, and stored at -80 °C for 
later sequence resurrection and identification. The expression plates were covered with 
Parafilm M and incubated at 37 °C for 24 hours, resulting in the overexpression of 
protein variants (Figure 3.5). The expression plates were centrifuged (1,000 rpm, 30 min, 
4 °C), decanted, and stored at -80 °C until screened. 
 
 
Figure 3.5. Example of library overexpression, randomly selected wells from LeuDH 
library 3. 
 
3.2.5 Development of a high-throughput screening assay 
 Three different assays were used over the course of evaluating the mutant 
libraries. Each subsequent assay method improved the quality of screening over previous 
methods.  
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 Libraries 2-5 were screened using an NAD+ auto-fluorescence assay (84-86). In 
an optimal system, sensitivities as low as 0.01 μM NAD(P)+ fluorophore were observed 
(87). Expression plates containing cell culture pellets were resuspended in 50 μL of B-Per 
Cell Lysing agent (Thermo Scientific). The resulting cell lysate was split into 20 μL 
aliquots in two separate plates, one reaction plate and one background plate. For the 
background plate, 180 μL of 1.1 mM NADH in 500 mM NH4Cl/NH4OH buffer pH 9.6 
was added to each well. This plate lacks the ketone substrate and will only result in 
background conversion rates. Similarly, 180 μL of the same buffer was added to the 
reaction plates, containing an additional 80 mM MIBK substrate. The plates were 
incubated at room temperature for 2 hours to allow for conversion.  
 After reaction, the fluorophore was generated through a pH shift. First the residual 
NADH was removed by adjusting the pH to 1.0 through the addition of 30 μL of 6N HCl 
and incubated for 25 minutes. At this pH value, the NADH will rapidly degrade while 
leaving the stable NAD+. To create the NAD+ fluorescence, the pH value was re-adjust 
to > 13.0 by adding 80 μL of 10 N NaOH and incubated in the dark for 2.5 hours. 
Fluorescence was measured using a Gemini Spectramax Microplate Spectrofluorometer 
(Molecular Devices, Downingtown, PA, USA) at an excitation wavelength of 360 nm 
and emission wavelength of 455 nm (Figure 3.6) (86). 
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Figure 3.6. NAD+ auto-fluorescence assay used in screening libraries 2 through 5. 
 
 Wells were ranked based upon the differential increase in fluorescence over the 
background plate. The results of a control experiment can be seen in Figure 3.7, 
demonstrating simulated conversion in cell lysate by the addition of various amounts of 
NAD+. NAD+ concentrations can be distinguished as low as 1-2 μmol to above 100 
μmol. This allows for the identification of very slight improvements in AmDH activity. 
The control experiment however, did not account for variations in expression levels 
between wells. This variation significantly reduced the sensitivity of the assay, and 
increased the identification of false positives. While the assay did yield successful 
mutants, its long reaction time and low signal to noise ratio were not ideal. 
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Figure 3.7. Sensitivity analysis of NAD+ auto-fluorescence assay with simulated 
conversion of NADH to NAD+ in BL21 cell lysate. 
 
 
 Libraries 6 and 7 were analyzed using a formazan-based assay developed by Chen 
et. al.(88). This assay takes advantage of the elevated activity in the deamination 
direction, giving the assay a better signal-to-noise ratio. The reaction scheme is 
represented in Figure 3.8. The enzymatic deamination activity is related to conversion of 
NAD+ cofactor to produce NADH, which is re-oxidized back to NAD+ by phenazine 
ethosulfate (PES, Sigma Aldrich). The resulting reduced PES subsequently reduces 2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride hydrate (INT, Sigma 
Aldrich) to create formazan. Formazan creates a deep red color which can be 
characterized by absorbance at 495 nm. Cell lysate was split in the same way as the 
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previous assay. Deamination buffer (180 μL) containing 1 mM NAD+, a catalytic amount 
of PES, and 0.1 M glycine buffer at pH 10.0 was added to the background plate. The 
reaction plate buffer also contained 80 mM 1,3-DMBA substrate. Plates were allowed to 
incubate for 30 min at room temperature before absorbance readings. 
 
 
Figure 3.8. Reaction scheme of formazan colorimetric assay (88). 
 
 
 The final and most simple assay (Figure 3.9) was used in the analysis of libraries 
8 through 11. The assay involved reading the wells’ absorbences at two wavelengths, 340 
nm and 600 nm. The increased absorbance at 340 nm corresponds to the production of 
NADH in the deamination of 1,3-DMBA, while the 600 nm reading roughly estimates  
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Figure 3.9. 340 nm absorbance-based amine detection assay with correlation of 




Figure 3.10. Correlation of LeuDH variants’ OD600 absorbance to background 
absorbance of 340 nm. 
 
y = 1.4893x + 0.2814 





























the biomass present in the well. The absorbance at 600 nm correlates strongly the 
background absorbance at 340 nm. (Figure 3.10) 
 The absorbance at 340 nm was normalized by the 600 nm absorbance reading for 
both the reaction and background plates. Variants were then scored by their proportional 
increase over the background observed in each well (Equation 3.1). This method 
significantly reduces the background noise of the assay by accounting for differences in 
expression levels, causing more accurate determination of enzymatic activity and 
decreasing false positives. The resulting quantity roughly estimates the specific activity 
of the overexpressed mutant protein. 
Background
Reaction
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3.3 Results and Discussion 
3.3.1 Identification of key residues in LeuDH 
 Leucine dehydrogenase from Bacillus stereothermophilus served as the initial 
protein scaffold. The only crystal structure currently available for leucine dehydrogenase 
(LeuDH) is an apo crystal structure from Bacillus sphaericus (PDB: 1LEH) (89). The 
determination of substrate–binding pocket interactions was instead based upon the holo 
crystal structures of an analogous protein, phenylalanine dehydrogenase (PheDH) from 
Rhodococcus sp. M4 (PDB: 1C1D and 1BW9) (90, 91). LeuDH and PheDH have a 
nearly identical secondary structure, with a backbone RMSD of only 0.234 Å, thus 
allowing for reasonable estimation of the interactions of the substrate with the binding 
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pocket. By using these structures in conjunction with knowledge of the reaction 
mechanism, amino acid residues surrounding the L-phenylalanine substrate binding 
pocket were identified (Figure 3.11). As previously discovered by Sekimoto et al., 
residues Lys80 and Asp115 are essential to the catalytic mechanism of the enzyme (92). 
These residues were excluded from our mutational libraries to conserve activity. 
 
 
Figure 3.11. Rhodococcus sp. M4 PheDH active site with bound L-phenylalanine and 
surrounding residues suitable for mutation (PDB: 1C1D) (90). 
 
 
 Conversely, residue Lys67 of LeuDH (Figure 3.11, PheDH: K66) directly 
interacts with the carbonyl moiety of the amino acid substrate through favorable charge 
interactions, and was chosen as the initial point of mutation (90, 92). Library 1 included 
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mutation to each of the remaining 19 amino acids. The resulting variants were cloned into 
pET28a vector and BL21 (DE3) competent cells for subsequent expression and His-tag 
purification. Each purified variant was analyzed spectrophotometrically at 340 nm to 
correlate the NADH/NAD+ cofactor conversion with the amination and deamination 
activity (93). 
 
Table 3.2. Grouping of active-site residues in B. stearothermophilus LeuDH. [a] 
Required screening for 95% statistical coverage of library sequence space. [b] Analyzed 
as individual mutants using purified protein. 
 






2 M63 M64 NNK 3066 
K66 K67 NNK 
3 G116 A112 GBC 3450 
P117 E113 NNT 
D118 D114 RAB 
V119 V115 RTK 
4 A38 L39 DBW 2910 
G39 G40 GBC 
G40 G41 DBW 
5 S189 H187 NNK 94 
6 A292 V290 DBS 969 
L295 V293 DBS 
7 G116 A112 NNK 94 
8 I293 I291 NNK 94 
9 E299 E296 NNK 94 
10 N263 N261 NNK 94 
11 K66 K67 DDK 969 




 The remaining binding pocket residues were broken into groups on the basis of 
CASTing principles to create libraries 2, 3, 4, and 6 (Table 3.2) (94). Regions of the 
binding pocket were grouped based upon their primary structure. The breadth of mutation 
at each position was then narrowed by their interactions based upon secondary structure. 
For example, every other amino acid side chain interacts with one another in a β-sheet, 
while only every fourth amino acid of an α-helix does the same. Interacting residues 
within each group were mutated simultaneously to capture any synergistic effects with 
neighboring residues. The mutational breadth at each position was constrained through 
degenerate codons to avoid amino acid substitutions which were likely detrimental to 
substrate binding (such as clear steric hindrance or unfavorable charge interactions). 
Removing a subset of detrimental amino acids limits the library size, so as to improve 
screening efficiency, while maintaining an increased chance of altering the substrate 
specificity. The number of colonies required to achieve 95% statistical coverage was 
calculated using equation 3.2 (31). 
 
      
        




 ;  (3.2) 
 N = number of colonies required in screening, 




 = proportion of the least represented codon 
 
 An example set of the degenerate codons applied in library 3 demonstrates the 
breadth of mutation over the four residues; Ala112, Glu113, Asp114, and Val115 (Table 
3.3). These four residues create a loop region along the binding pocket. The side chains 
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of residues 113 and 115 face toward the binding pocket, while 112 and 114 are directed 
outward. Residues 113 and 115 are believed to have strong interactions in stabilizing the 
imine intermediate, and for this reason will be widely mutated excluding only mutations 
which create unfavorable charge interactions or drastic steric hindrance. Conversely, 
residues 113 and 115 are likely to have less interaction. These residues’ mutations will be 
restricted to amino acids similar to the wild type residues, limiting mutational breadth to 
greatly reduce the required screening effort. 
 
Table 3.3. LeuDH library 3 distribution of degenerate codon amino acids at positions 113 
through 116. 
 
 Residue A112 E113 D114 V115 
Codon GBG NNT RAB RTK 
Ala [A] 1 1 0 0 
Arg [R] 0 1 0 0 
Asn [N] 0 1 2 0 
Asp [D] 0 1 2 0 
Cys [C] 0 1 0 0 
Gln [Q] 0 0 0 0 
Glu [E] 0 0 1 0 
Gly [G] 1 1 0 0 
His [H] 0 1 0 0 
Ile [I] 0 1 0 1 
Leu [L] 0 1 0 0 
Lys [K] 0 0 1 0 
Met [M] 0 0 0 1 
Phe [F] 0 1 0 0 
Pro [P] 0 1 0 0 
Ser [S] 0 2 0 0 
Thr [T] 0 1 0 0 
Trp [W] 0 0 0 0 
Tyr [Y] 0 1 0 0 
Val [V] 1 1 0 2 
Stop 0 0 0 0 
Codons 3 16 6 4 
AA 3 15 4 3 
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 Single residue libraries (5, 7, 8, and 9) were broadly mutated to all 20 amino acids 
(codon: NNK), because of their small size and the insignificant decrease in the required 
screening effort by applying a more restrictive degenerate codon. These residues were 
previously identified as influential in changing the substrate specificity of Bacillus 
sphaericus PheDH (88, 95).  
 Library 10 included mutation of binding pocket residue N261 (Figure 3.11, 
PheDH: N263). This position was not initially considered for mutation, despite its 
interaction with the carboxy moiety of the wild-type ligand, because of its involvement in 
binding the cofactor. However, as only the backbone amino group of the residue interacts 
with the cofactor, an exception was made for mutation at this position (Figure 3.12). The 
desired protein interactions with the cofactor will be mostly preserved after substitution 
of the side chain due to the universal peptide backbone structure. Being a single residue 
library, N261 was broadly mutated to all 20 amino acids (codon: NNK) 
 
 
Figure 3.12. Asn276 side chain interactions with the L-Phe substrate and backbone 




 Lastly, residues K67 and N261 were mutated simultaneously to create library 11 
because of their proximity in the binding pocket to the carboxyl moiety of the wild-type 
keto-acid substrate (2.6 Å and 2.9 Å, respectively). These residues have a synergistic 
effect with respect to binding the wild-type substrate’s carboxyl moiety, and interact 
directly with one another. 
3.3.2 Screening results via the high-throughput assay 
 Prior to screening, each library was checked for diversity at the target residues by 
sequencing randomly selected colonies (10-20 colonies), and comparing their distribution 
to the applied degenerate codon. Table 3.4 gives an example of 20 randomly selected 
wells from library.  The diversity at positions 39-41 indicates successful application of 
the mutagenesis protocol. Similar diversity was observed for all libraries. 
 The NAD+ auto-fluorescence assay (libraries 2-5) typically indicated a net 
negative value for non-beneficial mutations; the net relative fluorescence units (RFU) 
ranged from 0 to -500. Beneficial mutations gave net positive RFU, and were easily 
identifiable over background. 
 Figure 3.13 contains an example of a typical well plate analyzed using the 
absorbance-based assay with readings at 340 nm and 600 nm. Normalized absorbance 
values were calculated using Equation 3.1. Unsuccessful mutants show a normalized 
absorbance of approximately unity indicating no enhancement over background, while 













Table 3.4. Sequencing results of random LeuDH library 4 colonies to confirm diversity 
after the application of degenerate codons. 
 
Residue 39 40 41 
WT Leu Gly Gly 
1 Ala Val Ala 
2 STP Val Ser 
3 Phe Ala Ile 
4 Ala Val Ala 
5 Val Gly Thr 
6 Ala Val Ser 
7 Arg Ala Ser 
8 Val Gly Thr 
9 Cys Gly Thr 
10 Arg Val Ser 
11 Thr Gly Ile 
12 Thr Val Val 
13 Cys Val Ile 
14 Val Gly Ser 
15 Ala Arg Thr 
16 Thr Leu Ser 
17 Ile Gly STP 
18 Gly Gly Phe 
19 Val Ala Val 






Figure 3.13. LeuDH library 11, plate 9. An example of the results obtained for the high-
throughput absorbance-based assay. 
 
 
3.3.3 Characterization of library hits 
 The individual analysis of library 1 variants yielded a single beneficial mutation, 
Lys67Met that exhibited low, yet unprecedented activity for reductive amination (0.2 mU 
mg
-1
). A higher activity of 3.4 mU mg
-1
 was observed in the oxidative deamination of 
racemic 1,3-dimethyl butyl amine (1,3- DMBA). This mutation was carried over into the 
subsequent libraries. 
 The top performers of each high-throughput library (libraries 2-11) were sent for 
sequencing. The resulting sequences resulted in either the identification of beneficial 
mutations, or a large presence of parental variants. When beneficial mutations were 
identified, they often appeared multiple times in the sequenced hits. (Table 3.5)  The 
assay accurately and repeatedly identified beneficial mutations. When all or mostly 



























Table 3.5. LeuDH library 3 hit sequencing. These sequences represent the top 10 
performing colonies as indicated by the high-throughput assay. Repeat identifications of 
beneficial mutations are grouped at the top of the table. The top variants also returned the 
wild type sequence (italics). 
 
Residue    
A112 E113 D114 V115 
Ala Val Asp Val 
Ala Val Asp Val 
Ala Val Asp Val 
Ala Leu Asp Val 
Ala Leu Asp Val 
Val Ala Asp Met 
Gly Phe Asn Ile 
Ala Phe Asn Val 
Ala Glu Asp Val 
Ala Cys Asp Val 
 
 
identify further mutations. The enrichment of parental variants from a random library 
further supports the accuracy and robustness of the successful high-throughput screen.
 To get a more detailed determination of activity, each hit was further evaluated as 
purified protein. The hits were expressed and purified as described in Section 3.2.2. The 
purified protein’s activity was measured over a range of MIBK and 1,3-DMBA 
concentrations to determine kcat and KM of the amination and deamination reactions, 
respectively (Section 3.2.3). An example of these results can be seen in Table 3.6 for the 




Table 3.6. Characterization of LeuDH library 11 hits and comparison to previous best 





Residue Amination of MIBK Deamination of 1,3-DMBA 
Well K67 N261 Vmax KM Vmax KM 
Previous Top Variants 
   
 
   
 
Lib10 B2 Met Cys 0.236 ±0.04 21.6 ±11.5 1.76 ±0.20 14.8 ±6.1 
Lib10 H3 Met Val 0.084 ±0.01 21.01 ±8.5 2.894 ±0.44 33.1 ±13.0 
Library 11 Hits 
    
 
   
 
2B1 Ser Leu 0.331 ±0.07 18.7 ±11.7 2.350 ±0.26 41.9 ±9.7 
1C9 Ser Met 0.326 ±0.02 61.1 ±6.2 1.381 ±0.17 28.3 ±8.3 
1H4 Val Met 0.240 ±0.04 37.6 ±14.4 4.841 ±3.44 251.7 ±224 
2B11 Gly Leu 0.211 ±0.07 37.7 ±27.2 1.710 ±0.17 111.4 ±17.7 
1G2 Leu Leu 0.159 ±0.04 27.2 ±19.0 6.688 ±18 498.0 ±1551 
1A2 Leu Val 0.022 ±0.00 16.7 ±8.0 0.976 
 
33.8  
2E12 Gly Gly 2.4E+09 
 
3.8E+13  n.m. 
 
n.m.  
2G8 Gly Cys 7.2E+15 
 





Table 3.7. Accumulated mutations and resulting improvements to the specific activity 
and KM of LeuDH. Error values represent 95% confidence intervals of nonlinear fit 
parameters. 
[a]




 MIBK or 1,3-DMBA 
substrate (mM). 
[c]




 Separate variants gave 
maximum amination and deamination activity. 
  














  n.m.  n.m.  n.m.  
1 K67M 0.0002  n.m.  0.0034  n.m.  
3 K67M, E113V 0.015  n.m.  0.65  48  
6 K67M, E113V, V290C 0.016 ±0.004 70.2 ±35 1.02 ±0.41 77.1 ±66 
10
[d]
 K67M, E113V, N261V, V290C 0.089 ±0.007 10.3 ±3.6 2.81 ±0.44 30.9 ±13 
 K67M, E113V, N261C, V290C 0.236 ±0.04 21.6 ±12 1.76 ±0.20 14.8 ±6.0 






 After the screening of 11 libraries, four beneficial mutations were identified. 
Early rounds of mutation (libraries 1–9) identified either the wild-type sequence or single 
variants which improved the activity simultaneously in both the amination and 
deamination directions, thus allowing for the straightforward selection of the top variant. 
Library 10 identified distinct mutations for the most-active amination and deamination 
variants (Table 3.7). The most active amination and deamination mutations were with 
position Asn261 exchanged by Cys and Val, respectively. Library 11 further improved 
the amination activity by identifying synergistic mutations at positions 67 and 261, with 
these positions mutated from those identified in libraries 1 and 10. Libraries 2, 4, 5, and 
7-9 were unsuccessful in indentifying beneficial mutations, returning the parental 
sequence as hits. The final amine dehydrogenase contained four mutations, which are 
summarized in Table 3.7. The resulting quadruple variant (K67S/E113V/N261L/V290C) 
gave the highest amination activity of 0.69 U mg
-1
 with a corresponding kcat value of 0.46 
s
-1




    
  
 
       
      
 ;  (3.3) 
 v = reaction rate, 
 [P] = product concentration, 
 [S] = substrate concentration, 





Figure 3.14. Non-linear Michaelis-Menten fit of MIBK amination activity by LeuDH-
AmDH quadruple variant, K67S/E113V/N261L/V290C. 
 
 
3.4 Detailed characterization of library 11 hit 
3.4.1 Substrate specificity  
 The most-active variants showed amination and deamination activity toward a 
number of ketones and amines, respectively (Table 3.8). Since MIBK most closely 
mimics the wild-type keto-acid, 3-oxo-2-pentanoate, it was not surprisingly the most 
activity of the ketones tested. The detailed measurements of the final variant 
(K67S/E113V/N261L/V290C) kinetics showed enhanced amination activity over the 



























MIBK Conc. [mM] 
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Table 3.8. Substrate profile of top amination and deamination variants. 
[a]
Activity 
measured with 20 mM substrate. 
[b]
Specific activity in mU mg
-1
 protein, with the error 
representing one standard deviation. 
[c]
Activity measured with 40 mM racemic MBA, 20 









(R)-MBA 476.5 ±1.4 586.3 ±4.1 
(S)-MBA 5.0 ±0.0 1.6 ±0.0 
(R/S)-MBA
[c]
 484.0 ±3.5 784.6 ±13.4 
cyclohexylamine -  56.0 ±0.0 
cyclohexanone 18.8 ±0.0 123.4 ±3.5 
ethyl pyruvate 19.8 ±7.0 13.2 ±5.8 
methyl acetoacetate 4.5 ±0.7 4.5 ±0.6 
ethyl-3-oxohexanoate 6.4 ±4.9 14.0 ±1.2 
acetophenone 3.5 ±0.7 58.8 ±1.7 
 
 
3.4.2 Conversion and GDH cofactor recycle system 
 Initial rate kinetic measurements are used primarily in the determination of kinetic 
parameters to avoid second-order effects and product inhibition. The enzyme’s ability to 
reach complete substrate conversion cannot be determined from these initial rate 
experiments, and was instead evaluated by chiral GC of overnight conversion with a 
GDH recycle system. The GDH regenerates the expensive NADH by redox reaction of 
NAD+ and inexpensive glucose (Figure 3.1). In 1.5 mL reactions, replicates containing 
10 mM MIBK substrate was mixed with an excess of 12 mM glucose, 10 U GDH, and a 
catalytic amount of NADH (200 μM). Histag purified  K67S/E113V/N261L/V290C 
LeuDH-AmDH (0.13 mg) was added to each reaction and allowed to convert for 18 
hours. An additional 0.13 mg of enzyme was then added and allowed to react for 10 
hours to achieve the maximum conversion. One mL aliquots of the final reaction media  
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were adjusted to pH >13 by the addition of 100 μL of 10 N NaOH and derivatized in 
toluene according to the TFAA protocol (96). The replicates were then compared against 
a calibration curve derived by the same procedure with simulated levels of conversion 
(Figure 3.15), and an average substrate conversion of 92.5%±2.6 was achieved. 
3.4.3 
1
H NMR product confirmation 
 The product amine was additionally confirmed through 
1
H NMR. A 175 mL-scale 
amination reaction with GDH cofactor recycle was performed similar to previous 
conversion experiments. The reaction media was a 500mM NH4Cl/NH4OH buffer at pH 
9.6 containing; 10 mM MIBK, 12 mM glucose, 1 mM NADH, 2 mg GDH (85 U/mg). 
The histag purified quadruple variant (K67S/E113V/N261L/V290C @ 1314 μg/mL) was 
added in two 10 mL aliquots, initially and after 24 hrs. After 48 hours, the pH was 
increased (>12) with the addition 25 mL 10 N NaOH. The deprotonated amine product 
was then extracted with 40 mL methyl tert-butyl ether. Following separation, the solvent 
was removed through rotovap distillation, and the purified product was analyzed by 
1
H 
y = 102940x + 78822 
























NMR. The reaction showed 84.7% conversion, yielding 29.5 mg (R)-1,3-DMBA 
(>99.3% e.e.) with spectra matching the standard.  
 
1
H NMR (400 MHz, CDCl3) δ 2.94 (sex, 1H, J = 6.4 Hz), 1.65 (sep, 1H, 6.8 Hz), 1.24-
1.02 (m, 2H), 1.04 (d, 3H, 6.4 Hz), 0.89 (d, 6H, 6.8 Hz).  
 
3.4.4 Enantioselectivity 
 The enantioselectivity was initially estimated by measuring the deamination 
activity toward individual enantiomers of methylbenzylamine (MBA). MBA was used in 
place of 1,3-DMBA for selectivity experiments since it had a reasonable level of activity 
and individual enantiomers of MBA were commercially available (Sigma Aldrich). A 
preference towards (R)-MBA over the corresponding (S)-enantiomer was evident in the 
discrepancies between the deamination activities of 0.586 U mg
-1
 and 0.002 U mg
-1
, 
respectively. These preliminary results were corroborated through direct measurement of 
the enantioselectivity of the MIBK amination in producing chiral 1,3-DMBA.  
 Derivatization with trifluoroacetic anhydride (TFAA) (96) and chiral gas 
chromatography allowed for the separation and quantification of individual enantiomers. 
The derivatized 1,3-DMBA enantiomers gave adequate baseline separation of the peaks, 
with elution times of 47.5 and 48.9 min for the (S)- and (R)-enantiomers, respectively. 
(Figure 3.16) Overnight reactions were pH adjusted to 13 with 10 N NaOH and extracted 
from the aqueous phase into benzene. The amine was derivatized and concentrated 
through evaporation of benzene. The product was composed of the single (R)-enantiomer 
of DMBA. The product amine was injected in increasing concentrations until the (S)-
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enantiomer could be observed. The quadruple variant exhibited an e.e. of 99.8%. Pure 
enantiomers of 1,3-DMBA are not available commerically. Therefore, the product 
enantiomer was identified by optical rotation. Optical rotations of each enantiomer are 
represented in Table 3.9. The extracted product amine in methanol gave an optical 
rotation of -0.0039º, indicating the production of the (R)-enantiomer (97). This level of 
enantioselectivity was maintained even beyond 90% substrate conversion. 
 
 












Optical rotation @ 






 The thermostability of the top LeuDH-AmDH variants was compared to the wild 
type LeuDH by circular dichroism.  Each protein was histag purified and dialyzed in 50 
mM sodium phosphate buffer pH 8.0, 300 mM NaCl, removing the imidazole from the 
purification procedure. Each protein was diluted to 50 μg mL
-1
 in a 0.1 cm quartz cuvette 
for analysis. Ellipticity was measured at 222 nm, corresponding to the maximum 
ellipticity of the protein as indicated by the wavelength scan (Figure 3.17). Each protein 
was analyzed from 25 °C to 95 °C with a ramp rate of 1 °C min
-1
. All three proteins 
exhibited nearly identical unfolding with melting temperatures (TM) between 65 °C and 
68 °C, making any differences in stability difficult to characterize (Figure 3.18). The four 
mutations within the LeuDH binding pocket did not destabilize the protein scaffold 








Figure 3.18. Circular dichroism of wild type LeuDH and top LeuDH-AmDH variants 




 An amine dehydrogenase was successfully developed from an existing amino acid 
dehydrogenase template by active-site targeted protein engineering. Eleven rounds of 
directed evolution have completely altered the enzyme’s specificity and created 
















































including simultaneous mutation of neighboring residues to capture synergistic effects. 
These variants were screened by various high-throughput assays identifying minute 
increases in amination activity, and successful mutations were carried into future rounds 
of mutagenesis. 
 The largest improvements in activity were achieved by the cooperative mutation 
of residues K67 and N261. Their simultaneous mutation ultimately indentified the most 
active quadruple mutant, K67S/E113V/N261L/V290C with novel reductive amination 
activity of 0.69 U mg
-1
 with a corresponding kcat value of 0.46 s
-1
. Within the first round 
of mutation, the native activity toward L-Leu of 112 U mg
-1
 (98) was greatly decreased to 
less than 2 mU mg
-1
; completely inverting the enzyme’s specificity. The 
enantioselectivity of the wild-type enzyme was maintained despite the drastic changes to 
the binding pocket and yielded (R)-1,3-DMBA with an e.e. value of 99.8% at 92.5% 
conversion. This amine dehydrogenase exhibited activity toward a number of different 
substrates. The enzyme has also maintained its wild type stability making it an attractive 
catalyst in the synthesis of chiral amines. This is the first example of a cofactor-
dependent amine dehydrogenase capable of selectively synthesizing chiral amines from a 
prochiral ketone and free ammonia. 
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CHAPTER 4: DEVELOPMENT OF AN AMINE DEHYDROGENASE 
FROM PHENYLALANINE DEHYDROGENASE 
 
4.1 Introduction 
 As the field of protein engineering grows, the characterization of novel 
biocatalysts expands the repertoire of allowable reactions. Biocatalysis is emerging as an 
essential tool in the asymmetric catalysis of pertinent chemicals. Chiral intermediates 
play a particularly important role as building blocks to the pharmaceutical industry. 
Enantiomerically pure forms of active pharmaceutical ingredients (APIs) can lead to 
lower dosages, increased efficacy, and elimination of detrimental side-effects (99).  In 
2006, 80% of small-molecule drugs approved by FDA were chiral and 75% were single 
enantiomers (2). The production of chiral amines is of particular importance due to their 
highly active and diverse influence on biological functions. Amine-based 
pharmaceuticals have been used in a wide range of functions including; stimulants, 
decongestants, vasoconstrictors, and antidepressants.  
The production of chiral amines remains difficult through traditional chemical 
catalysis, and the direct amination of ketones with free ammonia to product chiral amines 
has been identified as one of the most aspired biocatalytic reactions challenging the 
pharmaceutical industry by the American Chemical Society’s Green Chemistry Institute, 
Pharmaceutical Roundtable (9). Recently, this reaction has been demonstrated by an 
amine dehydrogenase (AmDH) through the modification of leucine dehydrogenase 
(LeuDH) scaffold to accept ketone substrates (79).  This biocatalytic route of production 
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offers several advantages; elimination of heavy metals, high selectivity (99.8% e.e.) and 
conversion (> 92%), and improved atom economy. 
 Recently, alternative methods to the biocatalytic production of chiral amines have 
been shown to be effective. ω-Transaminases have been evolved to accept a number of 
ketone compounds, and are even being applied commercially in the production of 
sitagliptin (47, 63, 70, 71, 75, 76). ω-Transaminases potentially offer many of the same 
advantages as an AmDH with the exception of i) accepting free ammonia for amination, 
instead requiring the use of a sacrificial amine donor, and ii) overcoming equilibrium 
limitations to achieve full conversion. 
 In this chapter, we design a second example of an amine dehydrogenase catalyst 
based upon the scaffold of phenylalanine dehydrogenase (PheDH, EC 1.4.1.20). This 
PheDH-based amine dehydrogenase (PheDH-AmDH) offers several advantages 
including; increased specific activity over the LeuDH-based amine dehydrogenase 
(LeuDH-AmDH), amination of additional ketones, and increased tolerance to organic 
solvents. 
4.2 Comparison of dehydrogenases and gene selection 
 Leucine dehydrogenase from Bacillus stearothermophilus, the enzyme detailed in 
Chapter 3, belongs to the Glu-Leu-Phe-Val dehydrogenase sub-family (Accession 
number: cd05211; Appendix A.1) of proteins. The enzymes of this family are closely 
related in structure and function. Each enzyme similarly catalyzes the reversible 
amination and deamination of their respective keto- and amino acids with free ammonia, 
and is facilitated by the hydride transfer of an NAD(P)H cofactor. These enzymes consist 
of two domains separated by a deep cleft (Figure 4.1). One domain is responsible of 
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binding the substrate and contains residues involved in catalysis (100, 101). The other 
proteins’ domain responsible for binding the cofactor containing a characteristic βαβ  
structure, known as the Rossmann fold, and is highly conserved among these 
dehydrogenases (102). This conserved structure and functionality 
makes the Glu-Leu-Phe-Val dehydrogenase sub-family part of the larger domain 
superfamily NADB_Rossmann (Accession number: cl09931); easily identifiable through 
the NCBI’s Conserved Domain Database (103). 
 
 
Figure 4.1. Crystal structure of LeuDH Lysinibacillus sphaericus (PDB:1LEH) (89). The 
catalytic region (blue) and Rossmann-fold region (yellow) are divided by a deep cleft. 
The active site lies within this cleft indicated by the red arrow. 
 
 
 A subset of phenylalanine dehydrogenases were selected from the Glu-Leu-Phe-
Val dehydrogenase sub-family for comparison for use as a template for the PheDH-
AmDH. The four organisms; Bacillus badius Bachelor, Bacillus sphaericus, 
Rhodococcus sp. M4, and Sporosarcina ureae, were initially selected because of their 
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well characterized activities and substrate profiles present in literature (90, 104-108). The 
similarity and identity between these genes can be seen in Table 4.1. Ultimately, 
Rhodococcus sp. M4 was chosen because of the availability of several crystal structures 
with bound substrates (PDB: 1C1D, 1C1X, 1BW9, and 1BXG) (90, 91), and its high 
specific activity (100). This allows for detailed interactions of the enzyme-substrate 
complex to be drawn directly from the crystal structures. 
 
Table 4.1. Similarity and identity of select PheDHs with Bacillus stearothermophilus 























































































LeuDH Bacillus stearothermophilus - 54/36 66/48 71/50 69/48 
PheDH Rhodococcus sp. M4  - 49/32 49/32 51/31 
PheDH Bacillus badius   - 83/67 82/66 
PheDH Bacillus sphaericus    - 78/63 




4.3 Evolution of phenylalanine dehydrogenase from Rhodococcus sp. M4 
4.3.1 Wild-type gene synthesis, cloning, and overexpression 
 The wild-type gene sequence of phenylalanine dehydrogenase from Rhodococcus 
sp. M4 was attained from Brunhuber et al. (100). The nucleic acid sequence was 
synthesized by an external vendor (MWG Operon) and provided in a pUC57 vector. The 
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gene was amplified out of the host plasmid, along with the simultaneous insertion of 
restriction sites NdeI and HindIII (bold) using the primers; N-terminal 5’- 
GGGAATTCCATATGAGTATCGACAGCGCACTGAAC -3’, and C-terminal 5’- 
CCATGATTACGCCAAGCTTGC -3’. A second amplification was performed to insert 
a STOP codon at the C-terminus of the protein sequence and allow for proper translation 
and expression. The forward and reverse primers, 5'- 
CGACAACGACAGCGACTGCCTAGGGCCCGTCGACTGCAG -3' and 5'- 
CTGCAGTCGACGGGCCCTAGGCAGTCGCTGTCGTTGTCG -3' respectively, were 
used in this amplification. The final insert was then digested and ligated into pET28a for 
overexpression and histag purification as described in Sections 3.2.1 and 3.2.2. The wild-
type protein was successfully purified and activity confirmed (39.5 kDa, 46 U mg
-1
). 
4.3.2 Mutation and overexpression of AmDH 
 The wild-type gene was then mutated with the analogous mutations beneficial to 
creating AmDH in the LeuDH scaffold. These residues were identified through sequence 
alignment as shown in Figure 4.2. 
 
 
Figure 4.2. Truncated sequence alignment of LeuDH B. stearothermophilus and select 





 The K66M mutation was created by applying the primers, 5’- 
GGGGGCGATGACGTTGATGATGGCAGTGAGCAACCTTCC -3’ and 5’- 
GGAAGGTTGCTCACTGCCATCATCAACGTCATCGCCCCC -3’, in the overlap 
extension protocol described in Sambrook et al. (83). After sequence confirmation, 
overexpression of the K66M single mutant was attempted in pET28a vector and BL21 
competent cells. This overexpression was unsuccessful, and the protein was not 
expressed. The K66M mutant DNA was then used as a template for mutation back to the 
parental sequence, K66. Upon mutation back to the parental sequence, successful 
overexpression of the protein was restored. This indicated that the Rhodococcus sp. M4 
PheDH was not tolerant to mutation at this position without introducing difficulties in 
expression. An alternative PheDH gene from Bacillus badius was used in future 
experiments to circumvent these complex problems with overexpression. 
4.4 Evolution of phenylalanine dehydrogenase from Bacillus badius Bachelor 
 Phenylalanine dehydrogenase from Bacillus badius Bachelor was chosen as an 
alternative scaffold to the Rhodococcus sp. M4 gene. The B. badius gene has been shown 
to be reasonably active with a kcat value of 39 s
-1
 and has been extensively characterized 
in literature (105, 109-111). Another advantage of the B. badius PheDH is its increased 
similarity to the LeuDH scaffold (66% similarity) compared to the Rhodococcus sp. M4 
(54% similarity). This increased the chances of successful translation of AmDH 
mutations from the previous scaffold. 
 The Rhodococcus sp. M4 and B. badius PheDHs are very different from each 
other on a sequence level, sharing only 32% identity and 50% similarity. Coming from 
the same structural sub-family, they share a much stronger correlation in their folding 
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motifs. Since there currently is no crystal structure available for the B. badius PheDH, the 
sequence was folded over the 1BW9 crystal structure and superimposed over the original 
scaffold using SuperPose (112). The resulting B. badius structure is nearly identical to the 
1BW9 crystal structure with a backbone RMSD of only 1.69 Å (Figure 4.3), with the 
major deviation occurring at a loop region evident in the primary sequence. This tertiary 




Figure 4.3. SuperPose alignment of Rhodococcus sp. M4 PheDH, green (PDB: 1BW9) 
and B. badius PheDH structural overlay, red. The NADH and L-Phe substrates are shown 




4.4.1 Materials and Methods 
4.4.1.1 gDNA preparation, gene isolation and overexpression 
 Genomic DNA from Bacillus badius Bachelor (ATCC# 14574) was purchased 
from the American Type Culture Collection (ATCC, Manassas, VA). The PheDH gene 
could not be successfully amplified out of the fully intact genome. The genome had to 
instead be digested prior to amplification using restriction sites; BamHI, BglII, EcoRI, 
and NdeI. These restriction sites are known not to cut within the PheDH gene, but would 
cut at several instances within the organism’s genomic DNA. This allowed for a more 
manageable DNA template to amplify the PheDH gene. The gene was amplified using a 
standard PCR protocol (83) with the forward primer, 5'- 
GGAATTCCATATGAGCTTAGTAGAAAAAACATCCATCA -3' and reverse primer, 
5'- CCGCTCGAGTATTAGTTGCGAATATCCCATTTTG -3'. These primers 
simultaneously inserted the restriction sites NdeI and XhoI prior to and following the 
gene, respectively. The locations of the restriction sites are indicated by bold font with 
each primer. This made for simple digestion and ligation into either pET17b or pET28a 
plasmids. 
4.4.1.2 Protein purification 
PheDH from Bacillus badius was expressed and purified in a manner analogous to 
that described in Section 3.2.2. Successful IMAC purification with the histag was 
confirmed through SDS-PAGE of the purification fractions (Figure 4.4). Overexpression 
of the enzyme is indicated by a heavy band at 44 kDa in the clarified cell lysate and 
protein fractions. The removal of cellular proteins can be seen in the wash fractions. Faint 
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bands of these proteins are observable in the purified fraction only after overloading. 
Under normal loading conditions, only the purified PheDH band is visible. 
 
 
Figure 4.4. Histag purification of wild type B. badius PheDH. Lane L: Ladder, A: 
Clarified cell lysate, B: Unbound clarified cell lysate, C: 50 mM imidazole wash 1, D: 50 




4.4.1.3 Spectrophotometric assay 
The activity of the purified protein was evaluated using a spectrophotometric 
assay at 340 nm as described in Section 3.2.3 at 25 °C in various concentrations of 
NH4Cl/NH4OH buffer pH 9.6. 
4.4.1.4 Mutagenesis and library generation 
 After eleven rounds of mutagenesis, three mutations were previously identified to 
be most influential in creating reductive amination activity in a LeuDH-based scaffold; 
Lys67Met, Glu113Val, and Asn261Val (Chapter 3). Analogous mutations to these were 
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identified through sequence alignment and applied to a similar amino acid dehydrogenase 
scaffold, phenylalanine dehydrogenase (PheDH) from Bacillus badius (48% identity, 
66% similarity). Each of the point mutations, as well as combinations of these mutations, 
was evaluated for amination activity.  
 Mutants and libraries were generated using an analogous protocol to that 
described in Section 3.2.4, with the only difference that the restriction site XhoI was used 
in place of HindIII. Single and multiple variants containing mutations analogous to those 
found in ‘LeuDH-AmDH library 10’ were created using combinations of the primers in 
Table 4.2. LeuDH-AmDH library 11 had not yet been screened at the time of this 
experiment. The final variants were amplified from the respective mutational portions to 
yield the complete gene as described in the overlap extension protocol (83), and ligated 
into pET28a for subsequent expression and purification as detailed in Section 3.2.2. 
 The first library of PheDH-AmDH variants contained mutations at both positions 
K77 and N276. The directly substituted mutations from LeuDH-AmDH did not 
necessarily identify the optimal combination of mutations at these positions.  
 
Table 4.2. Mutational primers applied to B. badius PheDH to create mutations analogous 






   Primer   
K67M K77M Fwd 5' GCCTTTCCAAAGGAATGACTTACATGTGCGCGGCGTCCG 3' 
Rev 5' CGGACGCCGCGCACATGTAAGTCATTCCTTTGGAAAGGC 3' 
E113V T123V Fwd 5' GGCGGCCGTTTCTATACAGGTGTGGATATGGGAACGAATATGGAAGATTTC 3' 
Rev 5' GAAATCTTCCATATTCGTTCCCATATCCACACCTGTATAGAAACGGCCGCC 3' 
N261V N276V Fwd 5' GCAATCGCCGGTTCAGCCGTGAATCAGCTGCTTACGGAGGATCAC 3' 
Rev 5' GTGATCCTCCGTAAGCAGCTGATTCACGGCTGAACCGGCGATTGC 3' 
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Simultaneous mutation of these residues will identify any synergistic effects between 
their side chains. Since previous libraries had identified LeuDH K67M as a beneficial 
mutation, it was essential that the degenerate codon at that position contain methionine to 
ensure the identification of the best variant. The efficient NDT codon was excluded for 
this reason. With a two site library, codon selection must also be efficient to reduce the 
screening effort. A two site NNK library would require the screening of 3066 colonies, 
which is near the maximum screening capacity of the high throughput assay. The DDK 
codon greatly reduced the screening requirement to 969 colonies, while still including 














Ala [A]     2 
Arg [R] 1 1 3 
Asn [N] 1 1 1 
Asp [D] 1 1 1 
Cys [C] 1 1 1 
Gln [Q]     1 
Glu [E] 1   1 
Gly [G] 2 1 2 
His [H]   1 1 
Ile [I] 1 1 1 
Leu [L] 1 1 3 
Lys [K] 1   1 
Met [M] 1   1 
Phe [F] 1 1 1 
Pro [P]     2 
Ser [S] 1 1 3 
Thr [T]     2 
Trp [W] 1   1 
Tyr [Y] 1 1 1 
Val [V] 2 1 2 
Stop 1   1 
Codons 18 12 32 
AA 15 12 20 
 
4.4.1.5 Screening of LeuDH mutants and libraries 
Each of the single mutants and combinations of these mutations were individually 
expressed and purified. Each variant was evaluated for activity toward 20 mM 1,3-
DMBA using the 340 nm spectrophotometric assay (Section 3.2.3). The best combination 
of mutations was determined by the specific activity.  
The best variant was further characterized for activity toward para-fluoro phenyl 
acetone (PFPA). PheDH’s wild type keto-acid substrate is phenylpyruvate, and the 
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equivalent AmDH ketone substrate would be phenylacetone (Figure 4.5). Phenylacetone 
is not commercially available, because it is regulated as a Schedule 2 narcotic (113). This 
was overcome by the use of a fluorinated derivative, para-fluoro phenyl acetone (Sigma 
Aldrich) which is commercially available and unregulated. 
 
 
Figure 4.5. Wild type PheDH and PheDH-AmDH substrates. 
 
 
The evaluation of the LeuDH-AmDH mutations on the PheDH scaffold identified 
the double variant K77M N276V as the most active, with a kcat value of 0.128 s
-1
 and a 
reasonable KM value of 4.61 mM (Section 4.4.2.2). Future variants with activity below 
this level were no longer considered significance. This elevated activity allowed for the 
application of a stringent screening assay (Figure 4.6) in screening the K77DDK 
N276DDK library. Screening in the deamination direction to exploit the higher activity 





Figure 4.6. Forward screening assay applied to PheDH library 1 for reductive amination 
activity of para-fluoro phenyl acetone in 500 mM NH4Cl/NH4OH buffer pH 9.6, 200 μM 




necessary. Instead, the amination activity was directly evaluated using a similar 
absorbance-based assay. 
After mutagenesis, colonies were picked and expressed as described in Section 
3.2.4. As the expression plates thawed, the cell pellets were gently vortexed with 30 μL 
of B-PER to uniformly resuspend and lyse the cells. The crude cell lysate was split in 10 
μL aliquots into two plates; a reaction and background plate. A reaction mixture (200 μL) 
containing 10 mM PFPA and 200 μM NADH in 500 mM NH4Cl/NH4OH buffer was 
added to each well. The same mixture lacking PFPA was added to the background plate. 
Absorbance measurements at 340 nm and 600 nm began immediately unlike the previous 
end-point assays (Section 3.2.5), and continued periodically over the course of 1.5 hours. 
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Active variants were identified by the rate of change in absorbance at 340 nm, 
corresponding to the fastest activity. The wells exhibiting the fastest rate change over that 
of the background plate were selected for further characterization. Some variants 
consumed the cofactor too quickly (< 5 min) to be observed over multiple time points, 
and gave low absorbance in the initial time point. These variants were included for 
further characterization. The successful variants were sequenced (MWG Operon), and 
each unique sequence was expressed in pET28a/BL21 for histag purification and 
determination of kcat and KM values with PFPA. 
4.4.2 Results and Discussion 
4.4.2.1 Wild-type PheDH activity 
 The wild-type PheDH from B. badius was characterized to ensure proper 
expression and folding prior to mutation. The purified PheDH exhibited activity levels 
greater than 257 U mg
-1
 in the amination of phenylpyruvate (500 mM NH4Cl/NH4OH 
buffer pH 9.6, 200 μM NADH, 5 mM phenylpyruvate at 25 °C), and 39.5 U mg
-1
 in the 
deamination of L-Phe (0.1 M Glycine buffer pH 10.0, 1 mM NAD+, 20 mM L-Phe at 25 
°C). KM values were determined for the substrates when possible, and corresponded well 
to those values found in literature (110). Additionally, the KI value of ammonia was 
determined to be 5.0 M. The KM of phenylpyruvate could not be determined due to its 
high absorbance at the analytical wavelength. The wild-type enzyme was determined to 




4.4.2.2 Comparison of beneficial mutations identified in LeuDH-AmDH 
 To directly and easily create a basis of PheDH-AmDH activity, each of the 
mutations indentified in LeuDH-AmDH were tested individually and in combination on 
the PheDH scaffold for the identification of residues which were influential in creating 
AmDH activity. The specific activities of the variants with 1,3-DMBA can be seen in 
Table 4.4. 
  The PheDH double variant, K77M N276V was the best combination of the 
LeuDH mutations. Both of these residues are known to interact with the wild-type 
substrate at the carboxyl moiety, and their synergistic effects are reflected in the large 
increase in AmDH activity when compared to their individual substitutions.  
 
Table 4.4. AmDH activity on 1,3-DMBA and MIBK by PheDH variants derived from 
analogous LeuDH-AmDH mutations. Amination: 500 mM NH4Cl/NH4OH buffer pH 9.6, 
200 μM NADH, 40 mM MIBK at 25 °C, Deamination: 0.1 M Glycine buffer pH 10.0, 1 











40 mM MIBK, kcat (s
-1
) 
Wild Type Wild Type -------------------- No Activity -------------------- 
Lys67Met Lys77Met 0.0033 ±0.000 0.0009 ±0.000 
Glu113Val Thr123Val 0.0013 ±0.000 n.m. 

















0.0011 ±0.000 n.m. 
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4.4.2.3 Screening of library and hits characterization 
 Prior to the screening of the PheDH K77DDK N276DDK library, the diversity of 
the mutations were checked. Twenty colonies were sequenced to ensure the desired 
breadth of mutation was achieved at each position, and a large percentage of parental 
variants were not present.  
 A total of 36 wells were labeled as highly active by the assay for subsequent 
characterization. Sequencing of these hits yielded 21 unique pairs of mutations, each of 
 
Table 4.5. Randomly selected colonies of PheDH library 1 confirming diversity at 
positions K77 and N276 by successful application of overlap extension mutagenesis. 
 
Colony K77 N276 
1 Leu Trp 
2 Asn Phe 
3 Val Phe 
4 Val Asp 
5 Arg Gly 
6 Arg Asp 
7 Asn Lys 
8 Gly Ile 
9 Tyr Cys 
10 Ser Leu 
11 Gly Gly 
12 Trp Ile 
13 Glu Arg 
14 Asp Lys 
15 Trp Met 
16 Glu Lys 
17 Glu Glu 
18 Cys Cys 
19 Gly Leu 




which were transformed into a pET28a plasmid for subsequent expression and his-tag 
purification. These purified proteins were individually characterized for activity toward 
the amination of PFPA to more accurately determine which combination of mutations 
performed best (Table 4.6). All 21 pairs of mutations were active amine dehydrogenases, 
eight of which provided kcat values greater than 1 s
-1
 in the amination of PFPA. The top 
variant 1H4 contained the mutations K77S N276L with an apparent kcat value of 2.8 s
-1
 
and KM, PFPA value of 4.37 mM in 500 mM NH4Cl/NH4OH buffer pH 9.6 with 200 μM 
NADH. The K77W N276E variant also exhibited exceptionally high levels of activity 
with an apparent kcat value of 2.63 s
-1
 and a KM, PFPA value of 5.32 mM. The K77S N276L 
variant was selected as the top candidate for further characterization, since it had the 









Table 4.6. Characterization of histag purified PheDH library 1 hits. Kinetic parameters 
kcat and KM determined by non-linear fit for the amination of PFPA in 500 mM 




Non-Linear Michaelis Menten 
 Hit Residue Residue kcat (s
-1) KM (mM) 
1H4 Ser Leu 2.802 ±0.536 4.4 ±1.6 
7F10 Trp Glu 2.631 ±0.159 5.3 ±0.6 
4H6 Met Met 1.818 ±0.190 7.9 ±1.3 
7A3 Ser Met 1.513 ±1.900 42.4 ±50.0 
4D2 Ser Ser 1.307 ±0.364 14.5 ±5.2 
10F12 Cys Leu 1.285 ±0.246 3.5 ±1.4 
2F4 Met Leu 1.283 ±0.100 4.2 ±0.6 
3G7 Ser Val 1.055 ±0.185 4.4 ±1.5 
5A3 Met Cys 0.896 ±0.080 1.5 ±0.4 
8D10 Met Leu 0.858 ±0.175 4.6 ±1.8 
6D12 Ser Phe 0.792 ±0.180 22.2 ±0.4 
9G3 Met Ser 0.661 ±0.074 4.9 ±1.0 
10G6 Val Leu 0.558 ±0.064 3.3 ±0.8 
1E11 Cys Ile 0.549 ±0.062 7.7 ±1.4 
4A9 Gly Ile 0.339 ±0.065 5.9 ±2.0 
11E1 Ser Gly 0.275 ±0.066 6.8 ±2.7 
9A11 Gly Cys 0.029 ±0.000  -  
10A6 Ser Glu 0.024 ±0.013 9.0 ±7.6 
10H2 Trp Ile 0.019 ±0.010  -  
12D6 Trp Gly 0.017 ±0.023  -  





4.5 Characterization of PheDH-AmDH 
The K77S N276L variant was characterized in detail for a number of properties 
including; pertinent kinetic parameters, the breadth of substrate specificity, thermo-
stability, overall conversion, and enantioselectivity. 
4.5.1 AmDH activity and substrate specificity 
 Kinetic parameters, kcat and KM, were determined for the enzyme and each of the 
reductive amination substrates; respectively. The original assay conditions of 500 mM 
NH4Cl/NH4OH buffer did not saturate the enzyme with respect to NH3. The kcat value for 
this AmDH enzyme with all three substrates saturated in aqueous NH4Cl/NH4OH buffer 




C. This represents a near 15-fold enhancement above the 
maximum observed kcat of 0.46 s
-1
 of the previously developed LeuDH-AmDH. The 
increase in buffer concentration did have a salt effect upon the KM value of PFPA, which 
increased to 7.75 mM under saturated reaction conditions of 5 M NH4Cl/NH4OH buffer 
pH 9.6 with 200 μM NADH. The KM value for NADH remained low as with the wild-
type enzyme with a KM value of 23.9 μM. 
 The significant increase in the KM of NH3 (KM, NH3 = 1.27 M) seen in the 
conversion of para-fluoro phenyl acetone amination, as compared to the amination of 
phenylpyruvate (KM, NH3 = 64.5 mM) can be attributed to decreased activation of the 
alpha carbon caused by changes in electron density with the new substrate. The original 
phenylpyruvate structure has a carboxyl group neighboring the alpha carbon where the 
nucleophilic attack of ammonia occurs. This carboxyl moiety will lessen the electron 
density at the alpha carbon make the nucleophilic attack more favorable compared to the 
ketone substrate. 
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 The breath of the substrate profile was analyzed through the amination and 
deamination activity toward a number of different ketones and amines, respectively. The 
diversity of these ketones varied in structure from small aliphatic ketones such as 3-
methyl-2-butanone, to larger aromatic ketones with additional functionality, such as 
phenoxy-2-propanone. Several other ketone compounds were found to exhibit reasonable 
levels of activity. (Table 4.7) 
 
Table 4.7. Substrate specificity of top variant, K77S N276L PheDH. Amination in 500 
mM NH4Cl/NH4OH, pH 9.6, 200 μM NADH, 20 mM substrate at 25 °C. [*] 40 mM, 20 
mM of each enantiomer. [
†
] Deamination in 0.1 M glycine buffer, pH 10.0, 1 mM NAD+, 
20 mM substrate at 25 °C. 
 
Substrate  Activity  
(mU/mg)  




  1.9 ±1.8  cyclopentanone  0.9 ±0.5  
S-MBA
†
  < 1.0   cyclohexanone  27.5 ±1.4  
R/S-MBA*
,†
 0.5 ±0.2   ethylpyruvate  18.4 ±5.9  
MIBK  77.0 ±1.3   benzaldehyde  31.4 ±8.7  
1,3-DMBA
†
 166.3 ±0.0   2-methylcyclohexanone  19.3 ±1.1  
acetophenone  < 1.0   3-methylcyclohexanone  41.1 ±2.1  
phenoxy-2-propanone  540.8 ±6.9  3-methyl-2-butanone  72.7 ±1.4  
2-hexanone  155.7 ±1.4   1-Boc-piperidone  7.8 ±1.1  
3-hexanone  1.6 ±0.5   Benzyloxyacetic acid 22.6 ±0.7  




 The enzyme shows increased activity toward methyl-ketones versus those which 
are ethyl-ketones or cyclic-ketones. The top five most active ketones; PFPA, phenoxy-2-
propanone, 2-hexanone, methyl isobutyl ketone and 3-methyl-2-butanone are all methyl- 
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ketones. This specificity is also observed in the large differences in activity toward 2-
hexanone (155.7 mU/mg) versus 3-hexanone (1.6 mU/mg). Despite the structural 
similarities, the methyl-ketone 2-hexanone, exhibits approximately 100-fold higher 
activity. Similarly, the enzyme requires at least a one carbon linkage between the alpha 
carbon and the substrate’s phenyl ring. This is reflected by the unobservable activity 
toward acetophenone, as well as the low deamination activity of methyl benzyl amine. 
4.5.2 Thermostability 
 The thermostability of the AmDH was compared to its wild-type scaffold using 
two different methods, circular dichroism (CD) and a temperature versus activity profile. 
The mutation of the enzyme scaffold has affected the thermostability, in addition to the 
enzyme’s function. Both the wild-type PheDH and the AmDH exhibit similar 
characteristics in the loss of secondary structure as indicated through CD. Both enzymes 
showed the same gradual loss of structure at temperatures up to 30 degrees Celsius 
(Figure 4.7 and 4.8), implying that the cause for the early loss of structure is inherent in 
the wild-type protein. Beyond 30 degrees, there is an earlier onset in the pronounced loss 
of structure of the double variant compared to the wild type; however, the slope folded 
fraction over temperature stays constant, indicative of constant enthalpy of melting. The 
K77S N276L mutations have slightly destabilized the protein structure, resulting in a 




C less than the wild type. The specific cause for this change 
is difficult to determine. It likely to be either disruption of the ‘ideal’ packing of the wild-
type enzyme’s hydrophobic core or a net decrease in hydrophobicity by the amino acid 
substitutions which leads to a lower folding entropy (114, 115). 
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Figure 4.7. Fraction of folded PheDH/AmDH as measured by circular dichroism 
spectroscopy of wild type PheDH and top PheDH-AmDH variant, K77S N276L with 
normalized ellipticity representing the percentage of folded protein (protein 
concentrations 100 μg mL
-1
 in 50 mM sodium phosphate buffer pH 8.0). 
 
 
Figure 4.8. Semi-log plot of fraction of folded PheDH/AmDH as measured by circular 
dichroism spectroscopy of wild type PheDH and top PheDH-AmDH variant, K77S 
N276L with normalized ellipticity representing the percentage of folded protein (protein 
concentrations 100 μg mL
-1

















































 The thermostability of the double variant K77S N276L was additionally 
determined by a temperature versus activity plot (Figure 4.9). This plot shows the 
enzyme’s Arrhenius activation through the lower temperature range (10-45 °C), although 
this thermal activation should appear to be exponentially increasing (116). The near 
linear increase corresponds to a low activation energy of 241 J mol
-1
. The maximum 
specific activity was 11.6 U mg
-1
 at a temperature of 50 °C. Above 50 °C, the enzyme 
began to rapidly lose activity as a result of denaturation. This deactivation correlated well 
with the circular dichroism data, where a dramatic loss of secondary structure was 




Figure 4.9. Temperature vs. Activity of PheDH K77S N276L double variant. Amination 
activity measured in 5 M NH4Cl/NH4OH buffer pH 9.6, 200 μM NADH, 20 mM PFPA 


























4.5.2 Conversion with cofactor recycle system 
 A reaction system capable of high-level conversions was demonstrated by pairing 
the AmDH with a GDH cofactor recycle system. The GDH consumes glucose present in 
solution to cheaply and efficiently regenerate the NADH cofactor, allowing conversion to 
continue beyond stoichiometric depletion of NADH. In a 100 mL reaction volume 
containing 20 mM PFPA, conversion was allowed to continue for 48 hours followed by 
extraction and 
1
H-NMR to confirm the product formation and conversion levels. The 
addition of 7.48 mg of the AmDH enzyme converted 89.4% of the 4-fluorophenyl 
acetone substrate to the product 1-(4-fluorophenyl)-propane-2-amine over 48 hours with 
an isolated yield of 66.2%. Under the same reaction conditions, 17.46 mg of the AmDH 
enhanced the overall conversion to 93.8% and 73.9% yield. Evidence of chirality was 
indicated by different NMR signals of the C3 hydrogens (δ 2.67, 2.49) which are adjacent 
to the C2 stereocenter (117) (Figure 4.10).  
 
4-fluorophenyl acetone substrate; 
1




H NMR (400 MHz, CDCl3) δ 7.26-6.95 (m, 4H), 3.12 (sex, 1H, J = 3.9 Hz), 2.67 (dd, 




Figure 4.10. Evidence of chiral 1-(4-fluorophenyl)-propane-2-amine via 
1
H NMR. A) 
Sextuplet splitting representative of the proton at the chiral center. B) A pair of doublet-




Equally important to conversion is maintaining the selectivity of the enzyme after 
altering the substrate specificity. Preservation of the wild type (S)-selectivity towards 
phenylalanine will result in the asymmetric production of (R)-1-(4-fluorophenyl)-propyl-
2-amine due to a change in Cahn-Ingold-Prelaw priority. The product amine resulting 
from enzymatic conversion with the co-factor recycle was isolated and derivatized using 
trifluoroacetic anhydride for analysis via chiral gas chromatography. An enantiomeric 
excess of > 99.8% toward (R)-1-(4-fluorophenyl)-propyl-2-amine was confirmed, 
however, further resolution of the selectivity was limited by the separation capability of 
the chiral column (118). Throughout all experiments, the (S)-enantiomer remained below 
the detection limits. Even as the enzyme approaches levels of conversion beyond 90%, 
the high enantioselectivity toward (R)-1-(4-fluorophenyl)-propyl-2-amine is maintained. 
This renders the AmDH/GDH system a viable method for the production of chiral 
amines. 
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Confirmation of the (R)-selectivity was achieved through polarimetry, since single 
enantiomers of (4-fluorophenyl)-propyl-2-amine are not commerically available. 
Suspension of the isolated product amine in methanol resulted in a negative optical 
rotation (-1.73°, 10 cm path length at 0.3 mM amine), confirming the (R)-(-)-enantiomer 
to known standards (119). 
4.6 Conclusions 
Previous knowledge in the evolution of an amine dehydrogenase, particularly the 
influence of binding pocket residues Lys77 and Asn276, allowed for a direct route to an 
active AmDH from PheDH. With a reasonably active starting variant, a stringent high-
throughput screening of a single two-site library further enhanced the desired reductive 
amination activity to a kcat value of 6.85 s
-1
 at 25 °C. The high enantioselectivity was 
maintained throughout the evolution process. The enzyme’s e.e. value of > 99.8% toward 
the (R)-enantiomer, even after high levels of conversion, renders it an attractive candidate 
for the asymmetric production of chiral amines. The reaction can be simply and cheaply 
driven to conversions in excess of 90% when paired with a cofactor recycle system. 
Despite a 4.4 degree Celsius decrease in thermostability, the enzyme remains broadly 
activity over a large temperature range from 10 to 50 °C, with a maximum observed 
specific activity of 11.6 U mg
-1
. The novel AmDH exhibits amination activity towards a 
range of ketone substrates, which makes it a good starting point for further evolution to 





CHAPTER 5: BROADLY APPLICABLE MUTATIONS TO CREATE 
AMINE DEHYDROGENASE ACTIVITY 
5.1 Introduction 
 The previous development of two AmDHs (Chapters 3 and 4) has allowed for the 
novel conversion of a prochiral ketone and free ammonia to a chiral amine product. 
These enzymes open the possibility of new synthetic pathways and could be evolved 
toward target substrates. The availability of two scaffolds significantly expands the 
substrate specificity, especially with the large differences in binding pocket size and 
substrate functionality between LeuDH-AmDH and PheDH-AmDH. During the 
evolutionary route of producing these enzymes, the assays concurrently identified the 
mutations K67S and N261L (LeuDH nomenclature, and equivalent PheDH residues) as 
essential for amination activity. The mutation of these residues is believed to be broadly 
applicable across the Glu-Leu-Phe-Val dehydrogenase sub-family of enzymes. To test 
this hypothesis, a third scaffold from ValDH will be evolved at its analogous residues for 
AmDH activity, potentially giving credence to a family of AmDHs. 
5.2 Materials and Methods 
5.2.1 Selection of valine dehydrogenase from Glu-Leu-Phe-Val family 
 The Glu-Leu-Phe-Val dehydrogenase sub-family (Accession number: cd05211) 
contains a large number of characterized proteins which are further divided into smaller 
sub-families. The B. stearothermophilus LeuDH, Rhodococcus sp. M4 PheDH and B. 
badius PheDH all exist within this large sub-family, and are even further grouped in a 
smaller sub-family NAD_bind_Leu_Phe_Val_DH (Accession number: cd01075). This 
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smaller sub-family grouping is a result of their highly conserved binding motifs of the 
NADH cofactor. Glutamate dehydrogenases (GluDH) are not a part of this smaller 
family, but are grouped into two separate GluDH subfamilies (Accession number: 
cd01076 and cd05313) within the greater Glu-Leu-Phe-Val dehydrogenase sub-family. 
Consequently, ValDH exhibits a much higher sequence identity to PheDH and LeuDH 
(typically greater than 60%), and GluDHs are more distant relatives (typically near 30% 
identity). The higher identity will increase the likelihood of successful translation of 
AmDH mutations to the ValDH scaffold. ValDH was chosen as the scaffold for 
demonstration of the broad application of AmDH mutations. 
 Three ValDHs were selected as potential scaffolds due to their previous 
characterization in literature. All three proteins hail from the Streptomyces genus of 
Actinobacteria, Streptomyces coelicolor (120-122), Streptomyces fradiae (123-125), and 
Streptomyces cinnamonensis (122, 126, 127). All three species suffer from high guanine 
and cytosine (GC) content which can cause difficulty in PCR. ValDH from Streptomyces 
cinnamonensis was ultimately chosen as the scaffold, since it had been previously been 
overexpressed in a pET vector, E. coli BL21(DE3) expression system resulting in large 
amounts of soluble and functional protein in the cytoplasm (126). The resulting ValDH-
based AmDH (ValDH-AmDH) would convert 2-methyl-3-butanone to chiral 1,2-




Figure 5.1. Desired reductive amination activity of ValDH-AmDH converting 2-methyl-
3-butanone to (R)-1,2-dimethylpropylamine. 
 
 
5.2.2 Codon optimization of valine dehydrogenase Streptomyces cinnamonensis  
 The usage of unfavorable codons in a highly expressed gene in E. coli can 
decrease the translational rate (128, 129). With redundancy present in the genetic code 
for most amino acids, the unfavorable triplets can be replaced with more favorable 
codons representing the amino acid. For example, arginine codons AGA and AGG have a 
usage frequency below 0.2% are replaced with commonly used codons CGT and CGC. 
With these codons removed from the gene sequence prior to synthesis, the resulting 
construct will exhibit improved expression over the wild-type sequence while still 
encoding the identical peptide. Additionally, long stretches of consecutive GC-base pairs 
can cause difficulties in polymerase chain reaction (PCR) amplification of DNA. The 
ValDH gene from S. cinnamonensis has a GC-content of 71% which includes several 
long stretches of consecutive GC-base pairs as long as 19-base pairs. Codon selection 
was also optimized to remove these GC-rich regions from the gene and reduce the overall 




5.2.3 Gene synthesis, preparation, overexpression, and purification 
 The codon-optimized ValDH gene was synthesized by MWG Operon. The 
synthesis included the insertion of NdeI and HindIII restriction sites prior to and 
following the designed gene for simple digestion and ligation into pET28a plasmid. 
 The plasmid was prepared, transformed and expressed using the protocol 
described in Section 3.2.1. Expression at 30 °C, instead of 37 °C in auto-inducing 
MagicMedia™ was the only deviation from the described protocol. Protein was purified 
using the histag purification protocol described in Section 3.2.2. 
5.2.4 ValDH-AmDH K76DDK N273DDK library 
 The ValDH-AmDH library will be generated using an analogous protocol to that 
described in Section 3.2.4 by applying the primers described in the Table 5.1. The 
resulting screening requirement of the two site (K76DDK, N273DDK) library is 969 
colonies.  
 
Table 5.1. Mutational primers applied to S. cinnamonensis ValDH to create two-site 




   Primer   
K76 Fwd 5' CTGAGCCGTGGCATGAGCTATDDKAACGCGATGGCGGGTCT 3' 
Rev 5' AGACCCGCCATCGCGTTMHHATAGCTCATGCCACGGCTCAG 3' 
N273 Fwd 5' TGTGCGGTGCGGCAAACDDKCAGCTGGCGCATCCGG 3' 
Rev 5' CCGGATGCGCCAGCTGMHHGTTTGCCGCACCGCACA 3' 
  
 
 The resulting library will be picked and expressed according to Section 3.2.4, at a 
temperature at 30 °C. After checking the libraries diversity, it will be screened in the 
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same manner as the previously described PheDH-AmDH library (Chapter 4, Figure 4.6) 
with the substrate as the only difference. Instead of PFPA, 20 mM 2-methyl-3-butanone 
(2M3B) will be the ketone analog closest to the wild type keto-acid. 
5.3 Results and Discussion 
5.3.1 Characterization of wild-type ValDH activity 
 The wild-type ValDH was expressed to ensure proper expression and folding 
prior to mutation. Histag purification yielded functional ValDH protein at a concentration 
of 229 μg mL
-1
. The successful purification can be seen in the strong enrichment and 
isolation of a 43.3 kDa protein via SDS-PAGE (Figure 5.2). The resulting protein was 
screened for deamination of L-valine in a 250 mM sodium carbonate buffer, pH 10 
containing 1 mM NAD+. The specific activity, 16 U mg
-1
 matched the literature values 
for deamination (127), confirming the presence of functional protein. 
 
 
Figure 5.2. Histag purification of wild type S. cinnamonensis ValDH. Lane L: Ladder, A: 
Clarified cell lysate, B: Unbound clarified cell lysate, C: 50 mM imidazole wash 1, D: 50 




 Valine dehydrogenase from Streptococcus cinnamonensis was chosen from a 
subset of well characterized ValDHs as an example scaffold for the broad application of 
mutations K67S and N261L (LeuDH-AmDH). The ValDH gene has been codon-
optimized to avoid prolonged stretches of consecutive GC-base pairs, high overall GC-
content, and usage of rare codons. The optimized gene has been overexpressed in E. coli 
BL21 (DE3) competent cells and successfully purified over a Ni
2+
-column via IMAC 
using an N-terminal hexa-histag.  The resulting protein exhibited deamination activity 
levels similar to those reported in literature (16 U mg
-1
). The gene is prepared for 
mutagenesis generating library 1; a broad two-site library over the most influential 
residues for AmDH activity. Hits indicated by the absorbance based assay will be further 
characterized for detailed kinetic parameters and substrate specificity. 
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CHAPTER 6: RECOMMENDATIONS AND CONCLUSIONS 
6.1 Recommendations 
6.1.1 Further protein engineering of PheDH- and ValDH-AmDHs 
 Directed evolution has been successfully applied in many instances to improve 
the catalytic properties of enzymes (30, 58). The PheDH and ValDH scaffolds have not 
yet been subjected to the evolutionary process. Only the single PheDH library of residues 
K77DDK and N276DDK has been screened. There is still a large potential for 
identification of beneficial mutations by screening other residues of the scaffold. Slight 
adjustments in the distances between catalytic residues can have a strong effect on 
reaction rates (130, 131). The first-shell residues of the active AmDHs are responsible for 
both direct interactions with active-site residues and binding of the substrate, and should 
be evolved using a process similar to that applied to LeuDH-AmDH (Table 6.1). 
Optimization of these protein-substrate interacts should result in increased catalytic 
constant kcat and a lower KM value.  
 The residues A38 and F137 (Rh. sp. M4 PheDH) are of particular interest due to 
their interactions with the para-substituted region of the PheDH substrate (Figure 6.1). 
The para-fluoro substitution of phenyl acetone creates not only a larger, but more polar 
moiety at this position. Substituting the A38 with a more polar side chain, or decreasing 
the size of the F137 may lead to more favorable substrate binding. 
 Evaluation of these selected amino acids will allow us to further increase the 
amine dehydrogenase activity, while significantly reducing the sequence space by 







Table 6.1. Alignment of binding pocket residues for B. stearothermophilus LeuDH, 
Rhodococcus sp. M4 PheDH, B. badius PheDH, and S. cinnamonensis ValDH. 
 



































sis Rationale for mutation 
L39 A38 L49 L48 Residues interact with the para-
substituted region of the Phe substrate 
G40 G39 G50 G49 
G41 G40 G51 G50 
M64 M63 M74 M73 
Side chain interactions with neighboring 
Lysine 
K67 K66 K77 K76 
Direct interaction with the carboxyl of 
the keto-acid substrate, along with Asn. 
A112 G116 G122 A121 Residues interact with the posterior 
portion of the substrate, opposite the 
reacting ketone/amine. 
E113 P117 T123 C122 
D114 D118 D124 D123 
V115 V119 M125 V124 
T133 F137 V143 T142 
Residues interact with the para-
substituted region of the Phe substrate 
N261 N263 N276 N273 
Direct interaction with the carboxyl of 
the keto-acid substrate, along with Lys. 
V290 A292 L305 V302 Residues shape substrate binding pocket 






Figure 6.1. Binding pocket of Rhodococcus sp. PheDH with bond distances in Å between 
the L-Phe substrate C4 carbon and neighboring side chains of A38 and F137.  
 
6.1.2 Stabilization of AmDH scaffolds  
 To achieve a robust industrial enzyme process, high thermostability and activity 
of the enzyme catalyst are required. Numerous enzymes have been evolved to improve 
thermostability and tolerance to nonnative process conditions through a variety of 
strategies.  These strategies include introduction of disulfide bonds (132), improved core 
packing (133-136), increased rigidity (54, 115), and optimized surface charges (137, 
138). 
 Several online tools allow for the prediction of potential disulfide bond pairs, i.e. 
SS-BOND or GDAP (139, 140). An example analysis of the Rhodococcus sp. M4 PheDH 
using SS-BOND can be found in Appendix A.3.  This algorithm approximates the 
location of β-carbon atoms from the position of the backbone, and screens this set for 
suitable β-carbon to β-carbon distances and bond angles favorable for a disulfide bond. 
The final confirmations are energy minimized and reported in the output. These results 
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can then be further screened experimentally or computationally for their effect on protein 
stabilization. 
 The tight packing of the protein’s core is essential for stability, and the 
elimination of voids in the protein structure results in a decreased free energy. Recently 
developed software, RosettaHoles2 and RosettaVIP allow for the quantitative and visual 
assessment of the packing in the protein core (135, 136, 141). These flaws in core 
packing can then be improved by directed evolution to create more energetically-favored 
folded protein states. 
6.1.3 Formate dehydrogenase cofactor recycle systems 
 The application of NAD(P)H-dependent dehydrogenases, such as the 
aforementioned AmDHs, require the use of a cofactor regeneration system. The 
regeneration of the cofactor significantly reduces the substrate cost by requiring only 
catalytic amounts of the expensive cofactor, instead of large stoichiometric quantities. 
Glucose dehydrogenase (GDH) has been successfully demonstrated to regenerate the 
cofactor for the LeuDH-AmDH (79), but a more ideal cofactor recycle system would be 
formate dehydrogenase (FDH). FDH would allow for the same regeneration of cofactor, 
and simultaneously allow for improved atom economy (Table 6.2). Instead of supplying 
the additional glucose substrate for the GDH system, the formate dehydrogenase could 
rely on formate present in an ammonium formate buffer system. Formate dehydrogenases 
offer the additional advantage of having specific activities more closely to that of the 
AmDHs, approximately 10 U mg
-1 




Table 6.2. Mass efficiency estimation for GDH and FDH cofactor recycle systems. A 1 
L-basis was chosen with 100 mM substrate concentration and 92% conversion to product. 
 
GDH-based cofactor recycle 
 

















buffer 0.5 59.5 29.75 
 
NH4HCO2 
buffer 0.5 63.1 31.55 
NADH 0.0002 763 0.15 
 
NADH 0.0002 763 0.15 
MIBK 0.1 100.2 10.02 
 
MIBK 0.1 100.2 10.02 
Glucose 0.1 180.2 18.02 
 








         Product produced (92% conversion) 
 
Product produced (92% conversion) 
1,3-DMBA 0.092 101.2 9.31 
 
1,3-DMBA 0.092 101.2 9.31 
         Estimated mass efficiency 16.1% 
 
Estimated mass efficiency 22.3% 
 
 
6.1.4 Organic co-solvent systems  
 Enzymatic synthesis in non-aqueous media is an attractive alternative to 
traditional chemical synthesis (143). Many target active pharmaceutical intermediates, 
such as tetralones or diketones (Figure 6.2), have limited solubility in aqueous media. To 
increase the solubility, these substrates require the application of an organic cosolvent. 
Solvent selection is important and can greatly impact the hazard, environmental-
friendliness, and cost of synthesis (144). Ideally, the organic solvent would comply with 
ACS GCI Pharmaceutical Roundtable Solvent Selection Guide to maintain the green 
benefits of an enzymatic reaction (145). Amino acid dehydrogenases have only been 
sparsely studied in organic solvents (146), but their successful application will allow for 








 Preliminary experiments with PheDH-AmDH K77M N276V have shown activity 
with an acetone cosolvent. The enzyme tolerates acetone concentrations as high as 20% 
v/v. The PFPA substrate has a limited solubility of 40 mM in aqueous media, but was 
increased to 60 mM with the addition of acetone. The increased substrate concentration 
resulted in a 40% increase in the maximum observable kcat (Figure 6.3), from 0.11 s
-1
 in 
aqueous solution to a value of 0.26 s
-1
 with 20% acetone. The KM were affected by the 
addition of acetone, increasing from a value of 4.6 mM to 23.1 mM in aqueous and 20% 
acetone, respectively. Further evaluation of organic solvents, combined with evolution to 
solvent stability (146) will allow for further increases in conversion rates and specificity 




Figure 6.3. PheDH-AmDH K77M N276V observed rate enhancement with 20% acetone 
by elevating substrate concentration. 
 
6.1.5 Evolution toward pharmaceutical targets 
 The ability to alter a protein’s sequence, structure and function has allowed 
scientists to evolve proteins toward new functions. Novel function can be achieved by 
directed evolution, but this approach must be focused toward a particular substrate to 
achieve the desired specificity. As stated by Tawfik et al., the first rule of directed 
evolution is ‘you get what you select for’ (49). Directed evolution of the same residues 
screened to create the original AmDH, have the potential to create analogous amination 
of other ketones as achieved with ω-transaminases (17). 
6.1.6 Scale up and whole-cell systems for target substrates 
 Industrial application of biocatalysts requires the scale-up of enzymatic reactions 
from lab-scale to pilot and industrial scale. Scientific and economic considerations must 
be accounted for during catalyst application on an industrial scale. A lab-scale 

























the novel amine dehydrogenase system can be achieved through two routes; i) whole-cell 
catalysis containing a suitable co-expression system capable of cofactor recycle, ii) an 
enzyme membrane reactor capable of continuous production of chiral amine and co-
factor recycle. 
 With nearly equivalent specific activities, the AmDH (1-10 U mg
-1
) and formate 
dehydrogenase (FDH) from Candida boidinii (6 U mg
-1
) can simply be expressed on a 
dual gene plasmid, such as pETduet-1 (Merck Millipore, Billerica, MA) in E. coli BL21 
(DE3) competent cells. The resulting co-expression should give similar specific activities 
per gram of soluble protein allowing for successful catalysis. However, if future AmDHs 
have substantially higher activities a two plasmid approach may be required. This 
approach has been successfully applied to the whole-cell asymmetric reductive amination 
of α-keto acids which represents a useful methodology for the synthesis of α-amino acid 
L-leucine (147). LeuDH from B. cereus was chosen for the reductive amination and FDH 
from C. boidinii for the cofactor regeneration. The main challenge for successful co-
expression of this system was the large discrepancy of specific activity between the two 
enzymes; ~400 U/mg for LeuDH and only 6 U/mg for FDH. This obstacle was overcome 
creating a co-expression system based on the same inducible promoter, but locating the 
genes on two E. coli plasmids with different copy numbers. To compensate for its low 
activity, FDH was expressed in plasmid pAM3-25 which has a higher copy number. 
Conversely, LeuDH was expressed in plasmid pAM10-1, a medium copy number 
plasmid (148). The two plasmids were transformed into BW3110, an E. coli strain 
suitable for high-density fermentation (149). The resulting combination gave similar 
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specific activities per gram of soluble protein and in specific cases achieved nearly 100% 
conversion to L-leucine.  
 An alternative option to whole-cell catalysis is an enzyme membrane reactor 
(EMR); which have been successful in the industrial application of enzymatic processes. 
In these systems, enzymes do not require simultaneous expression and instead can be 
combined at the appropriate ratio within the reactor. EMR reactors do however require 
purification of the desired enzymes, which can be achieved through various purification 
techniques (8). This system would require use of the same AmDH and FDH enzymes as 
the whole-cell system. Each enzyme would be independently expressed and loaded to the 
reactor to yield similar specific activities per gram of protein. Reaction conditions such as 
flow rate, temperature, substrate concentration, and enzyme loading are optimized to 
increase conversion.  Enzymes can easily be contained within the reactor by restriction of 
the membrane pore size. The retention of the cofactor poses a more difficult problem. To 
keep the cofactor from penetrating the membrane, it may be enlarged with polyethylene 
glycol (PEG) (150). Otherwise, it can simply be recharged along with substrate. Lastly, 
this finalized reaction process would be used to isolate the reaction product (~ 10g) for 
analysis of chemical and enantiomeric purity.  
6.2 Conclusions 
 This work describes the development of a novel class of amine dehydrogenases 
for the synthesis of chiral amines. Directed evolution has successfully enhanced the 
binding and activity for an unnatural ketone substrate. Eleven rounds of directed 
evolution have completely altered the LeuDH enzyme’s specificity and created amination 
activity. Each round of mutagenesis focused on a region of the binding pocket, including 
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simultaneous mutation of neighboring residues to capture synergistic effects. These 
variants were screened by various high-throughput assays identifying minute increases in 
amination activity, and successful mutations were carried into future rounds of 
mutagenesis. 
 The largest improvements in activity were achieved by the cooperative mutation 
of residues K67 and N261. Their simultaneous mutation ultimately identified the most 
active quadruple mutant, K67S/E113V/N261L/V290C, with novel reductive amination 
activity of 0.69 U mg
-1
 with a corresponding kcat value of 0.46 s
-1
. Within the first round 
of mutation, the native activity toward L-Leu of 112 U mg
-1
 (98) was eradicated to less 
than 2 mU mg
-1
; completely altering the enzyme’s specificity. The enantioselectivity of 
the wild-type enzyme was maintained despite the drastic changes to the binding pocket 
and yielded (R)-1,3-DMBA with an e.e. value of 99.8% at 92.5% conversion. This 
LeuDH-AmDH exhibited activity toward a number of different substrates. The enzyme 
has also maintained its wild type stability making it an attractive catalyst in the synthesis 
of chiral amines. This was the first example of a cofactor-dependent amine 
dehydrogenase capable of selectively synthesizing chiral amines from a prochiral ketone 
and free ammonia. 
 The two most influential mutations in the LeuDH-AmDH were applied to second 
scaffold, PheDH from B. badius. A single two-site library, K77DDK N276DDK, directly 
identified a double variant with significantly increased AmDH activity. This double 
variant K77S N276L exhibited a kcat value of 6.85 s
-1
 in the reductive amination of PFPA 
to (R)-(+)-1-(4-fluorophenyl)-propane-2-amine. The high selectivity of the wild type 
enzyme was preserved throughout the evolution process. The PheDH-AmDH resulted in 
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an e.e. of > 99.8% toward the (R)-enantiomer, even after high levels of conversion, 
rendering it an attractive candidate for the asymmetric production of chiral amines. The 
reaction can be simply and cheaply driven to conversions in excess of 90% when paired 
with a cofactor recycle system. Despite a 4.4 degree Celsius decrease in thermostability, 
the enzyme remains broadly activity over a large temperature range from 10 to 50 °C, 
with a maximum observed specific activity of 11.6 U mg
-1
 (50 °C, and a pH value of 9.6). 
The novel AmDH exhibits amination activity towards a range of ketone substrates, which 
makes it a good starting point for further evolution to increase activity toward specific 
API targets. 
 The applicable breadth across the Glu-Leu-Phe-Val dehydrogenase sub-family of 
the two key mutations (PheDH: K77 N276) observed in creating AmDH will be tested 
upon a third scaffold, ValDH from Streptomyces cinnamonensis. ValDH exhibits many 
of the same folding and mechanistic features as the previously developed AmDHs. 
Through a similar application of directed evolution to the PheDH scaffold, a focused 
library of mutants will be screened for novel amination activity on the ValDH. The 
corresponding gene has been codon-optimized and prepared for expression in E. coli.   
 Future works in the development of amine dehydrogenases should be targeted to 
the industrial application of these enzymes. Activities can possibly be enhanced further 
through directed evolution to make for even more attractive industrial catalyst. Several 
other aspects pertaining to industrial application of a catalyst have yet to be addressed 
and should be the priority of future experiments. Stabilization, co-solvent systems and 
process scale up have the potential of resulting in a robust catalyst applicable to the 
asymmetric production of target APIs.  
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APPENDIX  
Appendix A.1 Glu-Leu-Phe-Val sub-family phylogenic tree 
 
Figure A.1. Glu-Leu-Phe-Val sub-family phylogenic tree, Accession number: cd05211. 
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 Appendix A.2 ValDH optimized codon sequence 
Table A.1. S. cinnamonensis ValDH optimized codon sequence 
 
1 CATATGACC GAAGCGGAT AACGGCGTG CTGCATACC CTGTTTCAT AGCGATCAG 
 
GTATACTGG CTTCGCCTA TTGCCGCAC GACGTATGG GACAAAGTA TCGCTAGTC 
55 GGTGGTCAT GAACAGGTG GTGCTGTGC CAGGATCGT GCGAGCGGT CTGAAAGCG 
 
CCACCAGTA CTTGTCCAC CACGACACG GTCCTAGCA CGCTCGCCA GACTTTCGC 
109 GTGATTGCG ATTCATAGC ACCGCGCTG GGTCCGGCA CTGGGTGGT ACCCGTTTT 
 
CACTAACGC TAAGTATCG TGGCGCGAC CCAGGCCGT GACCCACCA TGGGCAAAA 
163 TATCCGTAT GCGACCGAA GAAGAAGCG GTGGCTGAT GTGCTGAAC CTGAGCCGT 
 
ATAGGCATA CGCTGGCTT CTTCTTCGC CACCGACTA CACGACTTG GACTCGGCA 
217 GGCATGAGC TATAAAAAC GCGATGGCG GGTCTGGAT CATGGTGGG GGTAAAGCG 
 
CCGTACTCG ATATTTTTG CGCTACCGC CCAGACCTA GTACCACCC CCATTTCGC 
271 GTGATTATT GGCGATCCG GAACAGATT AAAAGCGAA GATCTGCTG CTGGCGTTT 
 
CACTAATAA CCGCTAGGC CTTGTCTAA TTTTCGCTT CTAGACGAC GACCGCAAA 
325 GGCCGTTTT GTGGCGAGC CTGGGTGGC CGTTATGTG ACCGCGTGC GATGTGGGC 
 
CCGGCAAAA CACCGCTCG GACCCACCG GCAATACAC TGGCGCACG CTACACCCG 
379 ACCTATGTG GCGGATATG GATGTGGTG GCACGTGAA TGCCGTTGG ACCACCGGT 
 
TGGATACAC CGCCTATAC CTACACCAC CGTGCACTT ACGGCAACC TGGTGGCCA 
433 CGTAGCCCG GAAAACGGT GGTGCGGGT GATAGCAGC GTGCTGACC GCGTTTGGC 
 
GCATCGGGC CTTTTGCCA CCACGCCCA CTATCGTCG CACGACTGG CGCAAACCG 
487 GTGTTTCAG GGCATGCGT GCGAGCGCG GAACATCTG TGGGGCGAT CCGAGCCTG 
 
CACAAAGTC CCGTACGCA CGCTCGCGC CTTGTAGAC ACCCCGCTA GGCTCGGAC 
541 CGTGGCCGT AAAGTGGGT GTGGCGGGT GTGGGCAAA GTGGGCCAT CATCTGGTG 
 
GCACCGGCA TTTCACCCA CACCGCCCA CACCCGTTT CACCCGGTA GTAGACCAC 
595 GAACATCTG CTGGAAGAT GGTGCGGAT GTGGTGATT ACCGATGTG CGTGAAGAA 
 
CTTGTAGAC GACCTTCTA CCACGCCTA CACCACTAA TGGCTACAC GCACTTCTT 
649 AGCGTGAAC CGTAGCACC CATAAACAT CCGAGCGTG ACCGCTGTG GCGGATACC 
 
TCGCACTTG GCATCGTGG GTATTTGTA GGCTCGCAC TGGCGACAC CGCCTATGG 
703 GAAGCGCTG ATTCGTACC GAAGGCCTG GATATTTAT GCTCCGTGC GCGCTGGGT 
 
CTTCGCGAC TAAGCATGG CTTCCGGAC CTATAAATA CGAGGCACG CGCGACCCA 
757 GGTGCGCTG GATGATGAT AGCGTGCCG GTGCTGACC GCTAAAGTG GTGTGCGGT 
 
CCACGCGAC CTACTACTA TCGCACGGC CACGACTGG CGATTTCAC CACACGCCA 
811 GCGGCAAAC AACCAGCTG GCGCATCCG GGTGTGGAA AAAGATCTG GCGGATCGT 
 
CGCCGTTTG TTGGTCGAC CGCGTAGGC CCACACCTT TTTCTAGAC CGCCTAGCA 
865 AGCATTCTG TATGCTCCG GATTATGTG GTGAACGCA GGTGGCGTG ATTCAGGTG 
 
TCGTAAGAC ATACGAGGC CTAATACAC CACTTGCGT CCACCGCAC TAAGTCCAC 
919 GCGGATGAA CTGCGTGGC TTTGATTTT GATCGTTGC AAAGCGAAA GCGAGCAAA 
 
CGCCTACTT GACGCACCG AAACTAAAA CTAGCAACG TTTCGCTTT CGCTCGTTT 
973 ATTTTTGAT ACCACCCTG GCGATTTTT GCGCGTGCG AAAGAAGAT GGCATTCCT 
 
TAAAAACTA TGGTGGGAC CGCTAAAAA CGCGCACGC TTTCTTCTA CCGTAAGGA 
1027 CCGGCTGCG GCTGCGGAT CGTATTGCG GAACAGCGT ATGAGCGAT GCGCGTTAA 
 
GGCCGACGC CGACGCCTA GCATAACGC CTTGTCGCA TACTCGCTA CGCGCAATT 
1081 AAGCTT 
     
 
TTCGAA 
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Appendix A.3 Example output of SS-BOND in Rhodococcus sp. M4, PDB: 1C1D 
THE FOLLOWING RESIDUE PAIRS MIGHT FORM A DISULFIDE 
 BRIDGE ACCORDING TO THEIR CB-CB DISTANCE. WHICH 
 LIES  BETWEEN 3.15 AND 4.50 ANGSTROM 
 CORRESPONDING TO CHI-3 ANGLES OF +/- 90, +/- 65.5 DEGREES 
 
   NR  RES1 --  RES2  NAME1 NAME2   CB DIST  CA DIST   
 
    1    5  --   50    ALA   ALA     4.454    5.915 
    2    5  --   53    ALA   LEU     3.961    6.224 
    3   10  --   30    GLY   ASP     4.314    4.301 
    4   12  --   29    MET   LEU     4.446    5.162 
    5   14  --   27    VAL   ILE     3.989    4.922 
    6   16  --   25    ARG   PHE     4.269    5.065 
    7   22  --   84    GLY   PRO     3.442    5.439 
    8   24  --   82    HIS   ALA     3.885    5.026 
    9   26  --   56    VAL   ALA     4.493    7.057 
   10   26  --   80    VAL   VAL     4.384    5.083 
   11   28  --   56    ARG   ALA     4.139    5.979 
   12   28  --   60    ARG   ALA     4.155    6.223 
   13   29  --   37    LEU   ALA     4.275    6.067 
   14   29  --   77    LEU   GLY     4.431    4.211 
   15   30  --   60    ASP   ALA     3.856    5.409 
   16   30  --   76    ASP   GLY     4.479    5.522 
   17   31  --   64    SER   THR     4.408    6.310 
   18   32  --   75    THR   GLY     4.076    4.389 
   19   35  --   74    GLY   MET     4.301    4.082 
   20   37  --   75    ALA   GLY     4.030    3.908 
   21   37  --   77    ALA   GLY     3.193    4.927 
   22   38  --   74    ALA   MET     4.353    6.422 
   23   38  --  114    ALA   TRP     4.489    4.724 
   24   39  --   63    GLY   MET     4.107    6.319 
   25   39  --   77    GLY   GLY     4.310    4.861 
   26   39  --   78    GLY   LYS     3.870    4.516 
   27   40  --  116    GLY   GLY     4.294    4.118 
   28   40  --  118    GLY   ASP     3.178    5.051 
   29   41  --   79    THR   SER     4.151    4.515 
   30   42  --  118    ARG   ASP     4.153    4.880 
   31   43  --   81    ALA   ILE     4.143    4.587 
   32   43  --  120    ALA   ASN     3.860    5.390 
   33   46  --   51    TYR   ASP     4.315    6.247 
   34   46  --   52    TYR   ALA     4.364    6.125 

















Figure A.2. A sequence alignment of B. stearothermophilus LeuDH, Rh. sp. M4 PheDH, 
B. badius PheDH, and S. cinnamonensis ValDH. 
 
  
1 6010 20 30 40 50(1)
----------MELFKYMETYDYEQVLFCQDKESGLKAIIAIHDTTLGPALGGTRMWMYNSLeuDH Bacillus stearothermophilus (1)
-----------MSIDSALNWDGEMTVTRFDRETGAHFVIRLDSTQLGPAAGGTRAAQYSQPheDH Rhodococcus sp. M4 (1)
MSLVEKTSIIKDFTLFEKMSEHEQVVFCNDPATGLRAIIAIHDTTLGPALGGCRMQPYNSPheDH Bacillus badius (1)
-HMTEADNGVLHTLFHSDQGGHEQVVLCQDRASGLKAVIAIHSTALGPALGGTRFYPYATValDH Streptomyces cinnamonensis (1)
  L E    ILDSI HADNWDHEQVVFCQDRESGLKAIIAIHSTTLGPALGGTRMWPYNSConsensus (1)
61 12070 80 90 100 110(61)
EEEALEDALRLARGMTYKNAAAGLNLGGGK-TVIIGDPRKDKNE----AMFRAFGRFIQGLeuDH Bacillus stearothermophilus (51)
LADALTDAGKLAGAMTLKMAVSNLPMGGGKSVIALPAPRHSIDPSTWARILRIHAENIDKPheDH Rhodococcus sp. M4 (50)
VEEALEDALRLSKGMTYKCAASDVDFGGGK-AVIIGDPQKDKSP----ELFRAFGQFVDSPheDH Bacillus badius (61)
EEEAVADVLNLSRGMSYKNAMAGLDHGGGK-AVIIGDPEQIKSE----DLLLAFGRFVASValDH Streptomyces cinnamonensis (60)
EEEALEDALRLARGMTYKNAAAGLDLGGGK AVIIGDPRKDKSP    DLLRAFGRFIDSConsensus (61)
121 180130 140 150 160 170(121)
LNGRYITAEDVGTTVADMDIIYQETDYVTGISPEFGSSGNPSPATAYGVYRGMKAAAKEALeuDH Bacillus stearothermophilus(106)
LSGNYWTGPDVNTNSADMDTLNDTTEFVFGRSLERGGAGSSAFTTAVGVFEAMKATVAHRPheDH Rhodococcus sp. M4(110)
LGGRFYTGTDMGTNMEDFIHAMKETNCIVGVPEAYGGGGDSSIPTAMGVLYGIKATNKMLPheDH Bacillus badius(116)
LGGRYVTACDVGTYVADMDVVARECRWTTGRSPENGGAGDSSVLTAFGVFQGMRASAEHLValDH Streptomyces cinnamonensis(115)
LGGRYWTA DVGTNVADMDII KETDFVTGRSPEFGGAGDSSI TAVGVF GMKATAKHLConsensus(121)
181 240190 200 210 220 230(181)
FGSDSLEGKVVAVQGVGNVAYHLCRHLHEEGAKLIVTDINKEVVARAVEEFG-----AKALeuDH Bacillus stearothermophilus(166)
G-LGSLDGLTVLVQGLGAVGGSLASLAAEAGAQLLVADTDTERVAHAVALG------HTAPheDH Rhodococcus sp. M4(170)
FGKDDLGGVTYAIQGLGKVGYKVAEGLLEEGAHLFVTDINEQTLEAIQEKAKTTSGSVTVPheDH Bacillus badius(176)
WGDPSLRGRKVGVAGVGKVGHHLVEHLLEDGADVVITDVREESVNRSTHKHPSV--TAVAValDH Streptomyces cinnamonensis(175)
FG DSLDGRTVAVQGLGKVGYHLAEHLLEEGA LIVTDINEESVARAVEKA S   SATAConsensus(181)
241 300250 260 270 280 290(241)
VDPNDIYGVECDIFAPCALGGIINDQTIPQLKAKVIAGSADNQLKEPRHGDIIHEMGIVYLeuDH Bacillus stearothermophilus(221)




301 360310 320 330 340 350(301)
APDYVINAGGVINVAD-ELYGYNRERAMKKIEQIYDNIEKVFAIAKRDNIPTYVAADRMALeuDH Bacillus stearothermophilus(281)
APDFVANAGGAIHLVGREVLGWSESVVHERAVAIGDTLNQVFEISDNDGVTPDEAARTLAPheDH Rhodococcus sp. M4(283)
APDYIVNSGGLIQVAD-ELYEVNKERVLAKTKHIYDAILEVYQQAELDQITTMEAANRMCPheDH Bacillus badius(296)
APDYVVNAGGVIQVAD-ELRGFDFDRCKAKASKIFDTTLAIFARAKEDGIPPAAAADRIAValDH Streptomyces cinnamonensis(293)
APDYVVNAGGVIQVAD ELYGFNKERVLAKA  IYDTIL VFAIAK DGITT EAADRMAConsensus(301)
361 388370(361)
EERIETMRKARSPFLQNGHHILSRRRARLeuDH Bacillus stearothermophilus(340)
GRRAREASTTTATA--------------PheDH Rhodococcus sp. M4(343)
EQRMAARGRRNSFFTSSVKPKWDIRN--PheDH Bacillus badius(355)
EQRMSDAR-KL-----------------ValDH Streptomyces cinnamonensis(352)
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